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ABSTRACT
Alcoholism, alcohol abuse or alcohol use disorder (AUD) is considered as a
major untreated epidemic health concerns in modern societies. According to the 2014
report of World Health Organization (WHO), alcoholism causes approximately 6% of
all cases of death every year. It has been evident that chronic alcohol consumption
leads to organ damage, and in some cases, it progresses to cirrhosis and carcinoma.
Some pharmacotherapy strategies have been proposed during decades to treat AUD;
however, the efficacy of these medications to reduce drinking or alcohol abstinence
remained controversial. Naltrexon, acamprosate, desulfiram, and nalmefen have been
approved by the US Food and Drug Administration (FDA) and the European
Medicines Agency (EMEA) for alcohol abstinence. However, clinical studies show
that the efficiency of these medications in AUD treatment is limited. As a result,
finding a targetable biomarker in alcoholic patients to decrease alcohol craving and
prevent organ damage remained as a major health challenge.

According to the

literatures, paracellular tight junction proteins are highly affected by ethanol (EtOH).
In this work, the effect of EtOH on the expression of paracellular proteins as well as
efflux transporters (mainly P-glycoprotein) was investigated. The effects of EtOH on
paracellular route of drug permeation as well as P-glycoprotein- mediated drug efflux
provide more insights onto how pharmacokinetic characteristics are impacted in
alcoholic individuals.

Understanding of the pharmacokinetic changes will lead to

dose-adjustment for drugs that are administered to alcoholic patients.

Moreover,

finding novel biomarkers to treat different stages of alcoholism would be another
beneficial outcome of this research.

Gastrointestinal (GI) tract is considered as the first organ to be affected by alcohol.
The highest EtOH concentration reaches to GI tract right after each alcohol drink.
Due to propensity of GI tract epithelium with the highest EtOH concentration entering
the body, more harmful effects would be predicted in GI tract after alcohol ingestion.
Hence, estimating the actual concentration of EtOH in GI lumen after each alcohol
intake and subsequently other organs seems to be beneficial. To address this question,
a full physiologically based pharmacokinetic (PBPK) model was developed for EtOH
as described in Manuscript I (to be submitted to the European Journal of
Pharmaceutics and Biopharmaceutics). This manuscript describes development of an
advanced dissolution, absorption, and metabolism (ADAM) model integrated into the
Simcyp Simulator® 15 for alcohol. In this work, three common alcoholic beverages
including beer (325 mg/kg body weight), wine (300 mg/kg body weight), and whisky
(400 mg/kg body weight) were selected to be investigated.

After simulation of

beverages ingestion, the concentration-time profile of EtOH in stomach and duodenum
as well as plasma and peripheral tissues was predicted. According to the results, the
highest EtOH concentration was observed in stomach right after beverage ingestion
and the concentration significantly decline during a 3-hour period. Eventually after
stomach, duodenal concentration was the highest. The theoretical concentrations of
EtOH in our model were validated according to the experimentally reported results.
Moreover, EtOH concentration-time profile in well- and poorly-perfused tissues was
estimated. Results present that liver and muscle showed the highest and the lowest
rate of EtOH absorption, respectively.

Manuscript II (to be submitted to the Journal of Molecular Pharmaceutics)
outlines the effect of clinically relevant EtOH concentrations on the expression and
functionality of P-glycoprotein (P-gp) in Caco-2 cell monolayer. EtOH did not show
significant alteration in cell viability at concentrations found in GI tract. To investigate
the EtOH effect on P-gp, expression of P- gp was induced by treating normal cells with
vinblastine (10 nM). Immunofluorescent (IF) images of normal and P- gp induced
Caco-2 showed that the abundance of P-gp decreased by increasing EtOH
concentration and treatment time. Moreover, the effect of EtOH on the abundance of
xenobiotic transporters in normal and P- gp induced Caco-2 cells was analyzed.
Sequential Windowed data independent Acquisition of the Total High-resolution Mass
Spectra (SWATH-MS) proteomics approach showed that the abundance of P-gp
polypeptides was decreased after treatment of normal and P- gp induced Caco-2 cells
with EtOH for 4 and 24 h. Moreover, Calcein-AM assay showed that by increasing
concentration of EtOH to 25 mM, the efflux activity of P-gp was reduced in P-gp
induced Caco-2 cells. Increasing EtOH concentration more than 25 mM did not show
significant effect on P-gp functionality.

Furthermore, EtOH effect on transport

parameters of talinolol (Tal, a P-gp substrate) and PF-5190457 (PF-57), an alcohol
craving treatment currently undergoing clinical trials) was investigated in the presence
and absence of verapamil (P-gp inhibitor). According to the results, EtOH showed
significant decrease in efflux ratio (ER) of Tal in Caco-2 cells treated with 50 mM
EtOH for 24 h in the presence of verapamil (200 µM). However, EtOH did not show
significant effect on ER of PF-57 in the presence or absence of verapamil.

Manuscript III (to be submitted to Biochimica et Biophysica Acta (BBA)
Biomembranes) outlines the effect of clinically relevant EtOH concentrations on the
organization of paracellular membrane proteins in Caco-2 cell monolayer. Neither
EtOH, nor its metabolite, acetaldehyde (AA), showed significant alteration in cell
viability at concentrations found in GI tract.

Transepithelial electrical resistance

(TEER) assay showed that the paracellular hyper permeability of Caco-2 cells induced
by EtOH and AA was reversible.

Fluorescent Lucifer yellow (LY) permeation

showed that paracellular transport of LY was enhanced after treatment of Caco-2 cells
with EtOH. Transmission electron microscopy (TEM) images of EtOH-treated Caco2 cells showed the disintegration of membrane proteins including tight junctions (TJs),
adherent junctions (AJs), and desmosomes (DS). Moreover, the Sequential Windowed
data independent Acquisition of the Total High-resolution Mass Spectra (SWATHMS) proteomics was used to analyze the EtOH effects on paracellular proteins.
SWATH-MS showed that the abundance of TJs, AJs, and DS were diminished after
treatment of Caco-2 cells with EtOH for 4 and 24 h.
Manuscript IV (to be submitted to the Journal of Proteomics–clinical
applications) outlines the proteome of sigmoid colon obtained from human subjects
using label- free quantification proteomics.

The sigmoid colon of healthy human

subjects was compared to alcoholic patients with and without liver disease. Moreover,
the proteome of GI tract in chronic-binge rat model was investigated and compared to
that in control rats. SWATH-MS proteomics exhibits as a prominent technique in
quantitative analysis of proteins from limited biopsy samples.

In this work, the

proteome of human sigmoid colon biopsies as well as alcoholic rat GI tracts were

studied. Results show that the expression level of some proteins in sigmoidal colon
samples of alcoholic patients was altered compared to the healthy subjects.
Significant differences were observed in expression of proteins in AWLDLQ subjects
compare to the HC. No significant difference was observed in the expression of any
investigated protein in ALD patients.

Moreover, the effect of chronic EtOH

consumption on proteins of different parts of GI tracts was examined in rat models.
Vimentin and desmin showed a significant induction in pCol of binge-chronic rat
models compare to the control group. The power of SWATH-MS proteomics in
analysis of clinical biopsies might be helpful in identification of biomarkers to cure
different stages of alcoholism.
In summary, analyzing the proteome of Caco-2 cell monolayer treated by EtOH
revealed alteration in efflux transporters (e.g., P-gp) as well as paracellular barrier
proteins (i.e., TJs, AJs, and DS). Mainly, EtOH-treatment showed decrease in the
expression level of paracellular barriers and efflux transporters. The proteomics
evidence were confirmed with immunofluorescent assay, transmission electron
microscopy (TEM) images, Calcein- AM assay, and transport behavior of talinolol (a
P-gp probe). Furthermore, analyzing the proteome of binge-chronic rat models as well
as human alcoholic patients with or without liver disease were accomplished. We
anticipate that proteomic analyses of GI tract from alcoholic patients would be
beneficial to explore protein biomarkers for early detection and treatment of alcoholrelated diseases in liver and GI tract. In this way, the power of mass spectrometry
proteomics (i.e., SWATH-MS) in analysis of clinical biopsies might be helpful in
identification of novel biomarkers to cure different stages of alcoholism.
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Abstract
A full physiologically based pharmacokinetic (PBPK) model was developed for
ethanol (EtOH) using advanced dissolution, absorption, and metabolism (ADAM)
model fully integrated into the Simcyp Simulator® 15 (Simcyp Ltd., Sheffield, UK).
Three alcoholic beverages including beer (325 mg/kg body weight), wine (300 mg/kg
body weight), and whisky (400 mg/kg body weight) were chosen to predict the
concentration-time profile of EtOH in stomach and duodenum as well as plasma and
peripheral tissues. Simcyp modeling overestimated the stomach EtOH concentrations
compared to the observed values. However, increased intragastric fluid in fed-state
resulted in predicting closer values to the observed data. The observed duodenal
EtOH concentrations were overestimated. Higher entered EtOH from the stomach and
the activity of EtOH metabolizing enzymes in stomach are reasons for EtOH
overestimation in duodenum. Furthermore, the observed EtOH plasma concentration
in both fasted and fed conditions were underestimated by the predicted values.
Overestimation of oxidative metabolism of alcohol in our model as well as the ADH
polymorphisms in the studied populations could be responsible for this variation.
Finally, EtOH concentration-time profile in well- and poorly-perfused tissues was
estimated.

Providing the tissue-specific bioavailability parameters for EtOH is

advantageous to estimate the drug-EtOH interactions in their site of action. Results
present that liver and muscle showed the highest and lowest rate of EtOH absorption,
respectively.
Keywords: Ethanol (EtOH), PBPK modeling, Simcyp ® simulator, ADAM model,
intragastric EtOH concentration, EtOH plasma concentration.
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Introduction
The effect of drinking alcohol on drug absorption and bioavailability has received
considerable attention during recent years.1-3 Ethanol (EtOH) alters the body exposure
to the extended-release drug formulations through induction of dose dumping.4-6
While, the increased release of the dosage incorporated in prolonged-release
formulations has serious safety concerns, FDA has recommended to characterize the
effect of alcohol on the release profile of drugs.5 Apart from the effect of alcohol on
drug release and solubility behaviors, many EtOH-drug interactions have been
reported.

7,

8

anticoagulants

For instance, analgesics
12

, and antidiabetics

13

9

, antidepressants

10

, antibiotics

11

,

have been proven to show adverse reactions in

acute and chronic alcohol drinkers. Hence, the alcohol destination in human body
could reveal its profound role in various metabolic pathways that affects the
metabolism and disposition of drug substances.
When alcohol is absorbed, it undergoes two main oxidative and non-oxidative
metabolic pathways.

Those include (i) reversible oxidative conversion to

acetaldehyde catalyzed by alcohol dehydrogenases (ADH1A, ADH1B*1, ADH1C*2,
and ADH4)

14-16

and cytochrome P450 2E1 (CYP2E1)

17

in liver and intestine

followed by irreversible oxidation to acetate and acetyl Co-A by aldehyde
dehydrogenase 2 (ALDH2)

18

, and acyl-coenzyme A synthetase short-chain family

member 2 (ACSS2) 19 ; (ii) EtOH involvement in sugars, amino and fatty acids through
acetyl Co-A; (iii) oxidation via the tricarboxylic acid (TCA) cycle to CO 2 ; and (iv)
non-oxidative conversion to fatty acid ethyl esters (FAEE) and phosphatidylethanols
20

. Fig. 1 shows a schematic illustration of EtOH role in different metabolic pathways
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occurring in human GI tract and liver (hepatocytes). In this scheme, EtOH oxidation
to acetaldehyde and acetate (Fig. 1a), conversion of acetate to acetyl CoA (Fig. 1b),
and acetyl CoA transformation to citrate and fatty acyl CoA (Figs 1c and d) have been
shown.
The actual site and magnitude of EtOH first-pass metabolism in human remained
controversial over the years. Some researches confirmed that a significant fraction of
administered EtOH is cleared by first-pass metabolism primarily in gastric mucosa.
Julkunen et al.,

21

, has shown that significant EtOH first-pass metabolism in rat is

taking place in GI tract, mainly due to the presence of ADH4 in stomach. Meanwhile,
other works suggested that approximately entire EtOH first-pass metabolism occurs in
liver and gastric metabolism accounts for a small fraction of total EtOH clearance.22
While determination of EtOH concentration in different organs is not easy to be
experimentally measured, development of an in silico model to predict the
concentration-time profile of EtOH in human tissues seems to be beneficial. One of
the most helpful theoretical approaches that widely used in drug discovery and
development is physiologically based pharmacokinetic (PBPK) modeling and
simulation methodology.23 The concept of PBPK modeling was first introduced by
Teorell

24

in 1937 and developed rapidly during recent years due to emerging

commercially available softwares (Simcyp®, GastroPlus™ , and PK-Sim®)

25

and ease

of access to preclinical data.26 Nowadays, a number of drug labels affirm that PBPK
modeling was used to conduct clinical studies.

Therefore, PBPK modeling is

considered as a powerful tool in prediction of clinical data via evaluation of intrinsic
(population properties, and genetics) and extrinsic (drug-drug interaction) factors. It

4

combines the physicochemical data for a compound with the predefined physiological
and biological properties of a specific population to obtain a mechanistic approach for
that compound in the biological system.27
In the current study, a full PBPK model was built in Simcyp Simulator® 15
(Simcyp Ltd., Sheffield, UK) to predict the concentration-time profile of EtOH in
human stomach and duodenum.

Subsequently, the predicted values for EtOH

concentrations in gastrointestinal (GI) tract and plasma in fasted- and fed-state were
validated according to the corresponded observed values reported in literature.
Moreover, the concentration-time profile of EtOH was predicted in liver, gut, brain,
kidney, pancreas, spleen, skin, heart, muscle, and lung after ingestion of three
common alcoholic beverages (beer, wine, and whisky). Finally, the bioavailability
parameters of EtOH including area under the plasma concentration-time curve (AUC),
maximum concentration observed (Cmax ), and time to achieve Cmax (Tmax ) were
predicted and discussed in various tissues in fasted- and fed-states.

2. Methods and modeling approaches
2.1. EtOH PBPK model
A whole-body PBPK model was constructed according to the advanced
dissolution, absorption, and metabolism (ADAM) model integrated in Simcyp® (Fig.
2). In this model, GI tract is divided into nine parts including stomach, duodenum,
jejunum, ileum, and colon comprising of 1, 1, 2, 4, and 1 segments, respectively. This
model shows the body as composed of 13 tissue compartments and 2 blood
compartments (arterial and venous pools). The methodology and structure of the

5

Simcyp® population-based PBPK modeling was described in detail, previously

28-30

.

Anatomical and physiological parameters were modified according to the published
literatures when it was essential (Table 1).
The simulation of fasted-and fed-state gastrointestinal concentration of EtOH
after ingestion of three common alcoholic beverages was implemented onto a PBPK
modeling platform (Simcyp® Simulator) and was validated based on the in vivo data
obtained from literature.

Physicochemical properties, physiological/population

details, and trial design used for EtOH modeling have been summarized in Table 1.
In all trial designs standard adult body weight was set as 70 kg.31 Three common
alcoholic beverages, including beer (325 mg EtOH/kg body weight, 500 mL), wine
(300 mg EtOH/kg body weight, 200 mL), and whisky (400 mg EtOH/kg body weight,
80 mL) were modeled in fasted- and fed-state using healthy human adult population.
In the modeling of fed-state, a volume of 250 mL of liquid meal was applied and
initial volume of stomach fluid was modified accordingly in population details.
Furthermore, other model input parameters such as, mean gastric emptying time,
initial volume of stomach fluid, volume of intake alcohol, and dosage were retrieved
from the literature and used for model development (Table 1).

2.2. EtOH absorption, distribution, and elimination
After ingestion of alcoholic beverages orally, EtOH is absorbed rapidly from GI
tract via passive diffusion.32 The EtOH absorption starts from mouth and continues
along the GI tract. About 15% of the initial EtOH dose is absorbed into stomach in
fasted state, while only 30% of alcohol is passed to the GI tract once EtOH is

6

administered with food. 22 According to the ADAM model EtOH oral absorption from
luminal fluid to enterocytes was incorporated into unstirred boundary layer (UBL)
(Simcyp® manual).

A permeability- limited membrane (basolateral side of

enterocytes), which separates the enterocytes from intestinal interstitial fluid (ISF), is
considered as the second step. Finally, a lymphatic route of absorption facilitates the
EtOH entering systemic circulation.
Although the predominant site of EtOH metabolism is liver, the presence of ADH
isozymes in mucosa of stomach, duodenum and jejunum begins the alcohol
metabolism before liver.33 The presence of ADH4 in stomach and upper sides of GI
tract are proposed to be responsible for first pass metabolism of EtOH before reaching
to liver.32 Less than 2% of the ingested dose is metabolizing by gastric ADH4.22
While, almost the whole EtOH elimination is taking place in liver, less than 10% of
alcohol is excreted from lung, kidney, and skin. The breath alcohol clearance is 0.16
L/h, renal clearance is 0.06 L/h, and sweat clearance is 0.02 L/h.34 Additional sites of
EtOH clearance that were reported in the previously published literatures were applied
in this modeling to simulate more realistic pharmacokinetic behavior.

2.3. The genetics of alcohol metabolism by ADHs
The list of the involved ADHs in EtOH metabolism and their corresponding
Michaelis-Menten kinetic parameters has been shown in Table 2. According to the
table, there are several forms of ADHs named from ADH1 to ADH7.

Gene

polymorphism exists for some of these enzymes, while the well-known of which
identified for ADH1. Three types of ADH1 that occurred in human populations are

7

ADH1A, ADH1B, and ADH1C.14 Among them, the most important polymorphisms
have been identified for gene ADH1B, including ADH1B*1, ADH1B*2, and
ADH1B*3.14,

35

ADH1B*2 is very common in East Asian populations, relatively

common in Middle East people, and very rare in European and African populations.
Researches show that people who carry ADH1B*2, and ADH1B*3 alleles are less
prone to be alcoholic. It means that these alleles have protective function against the
alcoholism in Caucasian and Asian populations who carry those alleles. ADH1B*3
polymorphism is less in overall populations but it is prevalent in African and AfricanAmerican populations, meanwhile this allele is rare elsewhere.36-38

While, EtOH

concentration in Caucasian human healthy volunteers was simulated in this study, the
kinetic parameters for ADH1A, ADH1B*1, ADH1C*2, and ADH4 were used. In
addition, hepatic CYP2E1 was also considered for the model development.

2.4. Simulation of Ethanol concentration in stomach, duodenum, plasma, and other
tissues
The EtOH concentration in stomach and duodenum after ingestion of three
common alcoholic beverages was predicted and compared to the observed available
data. Rubbens et al., have reported the EtOH concentration in stomach and duodenum
of human healthy volunteers using head space gas chromatography in fastedfed-state

40

39

and

, previously. To extract the numerical data from the published literature,

plot digitizer software (http://arohatgi.info/WebPlotDigitizer) was used. Moreover,
the plasma alcohol concentration-time profile was predicted and compared to the
observed data reported by Levitt et al.22 Moreover, the concentration-time profile of

8

EtOH in GI tract, liver, brain, kidney, pancreas, spleen, skin, heart, muscle, and lung
after ingestion of three common alcoholic beverages (beer, wine, and whisky) were
simulated.

3. Results
3.1. EtOH concentration-time profile in stomach and duodenum
Fig. 3 and 4 show the EtOH concentration-time profiles in stomach and
duodenum of healthy human volunteers after drinking alcoholic beverages in fastedand fed-state. In these plots, Simcyp® predictions versus observed data reported by
Rubbens and co-workers39, 40 are illustrated together. Fig. 3a) shows the observed and
predicted EtOH concentration-time profiles in stomach after beer (500 mL) intake.
Based on the results, no significant difference was observed in experimental and
theoretical values for stomach EtOH concentration neither in fasted- nor in fed-state
(Fig. 3a and b). Fig. 3c shows approximately two times overestimation of Cmax after
ingestion of wine (200 mL) in predicted EtOH concentration compare to the observed
values in fasted-state stomach.

After 50 min, predicted and observed EtOH

concentrations were aligned with each other. According to the Fig. 3d, predicted and
observed EtOH concentration-time profiles in fed-state found to be in good agreement
with each other. Fig. 3e illustrates EtOH profile after ingestion of whisky (80 mL) in
fasted-state. The initial predicted EtOH concentration was two times higher than that
in the observed experiments; however, after 30 min they became aligned. Fig. 3f
indicates EtOH profile after consumption of the same amount of whisky in fed-state.
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Results show that there is no significant difference in the predicted versus observed
profiles of EtOH in stomach.
The EtOH concentration-time profile in duodenum of healthy human volunteers
in fasted- (Fig. 4a) and fed-state (Fig. 4b) after beer intake are shown. According to
Fig. 4a, the predicted EtOH concentration values were overestimated compared to the
observed values. However, the observed and predicted concentrations show similar
trends after 40 min of drink. Based on the illustrated graphs for the predicted and
observed EtOH concentrations in Fig. 4b, the predicted EtOH concentration at the
maximum value was ~ 26% overestimated compare to the observed value. Fig. 4c and
d show the EtOH concentration-time profile in duodenum after wine intake in fastedand fed-state, respectively. The predicted Cmax of EtOH in fasted- and fed-state is
approximately two times higher than that in the observed graphs. Fig. 4e shows the
overestimation of EtOH concentration in fasted-state after ingestion of whisky.
According to the graphs, the predicted and observed results were the same after 30
min of drink. Fig. 4f illustrates that predicted EtOH concentration at C max is two times
greater than that in the observed plot, while the difference between predicted and
observed values for EtOH concentration decreased by the time.

3.2. Key bioavailability parameters of EtOH in stomach and duodenum
Table 3 shows key bioavailability parameters of EtOH in fasted-and fed-state
after intake of alcoholic beverages. It summarizes C max , Tmax , and AUC of EtOH after
drinking alcoholic beverages.
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Results for beer show that Cmax of EtOH in fasted-state stomach is higher than
that in fed-state. Similar trend was observed in duodenal EtOH C max in fasted- versus
fed-state. While, duodenal Cmax of EtOH was decreased from 29.76 g/L in fasted-state
to 16.67 g/L in fed-state, Tmax was roughly doubled (Table 3). According to the
obtained data for AUC0-180 , there is a significant increase in AUC 0-180 of EtOH in fedstate stomach compare to fasted-state. However, the increased AUC0-180 in fed-state
duodenum was not as much. In the case of wine, C max of EtOH in fed-state stomach
was lower than that in fasted-state. Likewise, duodenal EtOH Cmax in fed-state was
less than that in fasted-state. Duodenal EtOH Tmax in fed-state was more than two
times greater than that in fasted-state (Table 3). AUC0-180 results for wine show
increased values in fed-state of stomach and duodenum compare to the same AUC 0-180
values in fasted-state. According to Table 3, Cmax of EtOH in fasted-state stomach
after ingestion of whisky was 232.62 g/L, which is three times greater than that in fedstate stomach. Similarly, higher duodenal Cmax was observed in fasted-state than that
in fed-state.

Tmax of EtOH after whisky ingestion was comparable with the Tmax

obtained for wine in duodenal fasted- and fed-state. Interestingly, AUC0-180 of EtOH
did not show any significant alteration in stomach and duodenum from fasted- to fedstate.

3.3. EtOH fraction dose absorbed and metabolized in GI tract
Fig. 5 shows the EtOH fraction dose absorbed (Fabs) and fraction dose
metabolized (Fmet ) after ingestion of different alcoholic beverages. Fig. 5a and b
illustrate Fabs and Fmet of EtOH after beer intake. No significant difference in EtOH
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Fabs and Fmet in different parts of GI tract was detected between fasted- and fed-state.
Similar pattern was observed in EtOH Fabs and Fmet following wine (Fig. 5c and d) and
whisky (Fig. 5e and f) administration. In all depicted graphs, the highest Fabs and Fmet
were corresponded to the upper GI tract sides which decreased by moving toward the
lower GI tract areas.

3.4. EtOH plasma concentration-time profile
Fig. 6 shows Simcyp® predicted plasma EtOH concentration-time profile after
intake of beer, wine and whisky in fasted- (a) and fed-state (b). In order to validate
the predicted EtOH concentration-time profiles, the experimentally reported values for
EtOH concentration, which was administered orally (150 mg/kg body weight) in
fasted- and fed-state

22

, were also illustrated.

Fig. 6a shows the predicted EtOH

profile in plasma after ingestion of three different alcoholic beverages as long as the
observed values reported by Levitt et al 22 for plasma EtOH plasma concentration in
fasted-state. Fig. 6a shows that the observed EtOH Cmax in plasma was 290.3 mg/L,
while the predicted EtOH plasma Cmax was 191.0, 117.0, and 97.5 mg/L after
administration of whisky, beer, and wine in fasted-state, respectively.
According to the Fig. 6a, the predicted EtOH Cmax after ingestion of whisky was
34% underestimated the observed EtOH plasma concentration in fasted-state. After
50 min of alcohol administration, the predicted and observed EtOH concentration
values more aligned with each other. (Fig. 6b) shows that the highest predicted EtOH
concentration after ingestion of whisky was ~ 60% underestimated the observed
plasma EtOH Cmax .
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Table 4 summarizes the pharmacokinetic parameters of EtOH in plasma obtained
from Simcyp® simulation in fasted- and fed-state. According to Table 4, Tmax for
EtOH was between 23.56 min for wine in fasted-state to 37.82 min for whisky in fedstate. For all the alcoholic drinks, the obtained AUC0-∞ in fed-states was lower than
that in fasted-state. The lowest AUC0-∞ was 37.46 mg·h/L for fed-state wine and the
highest was 201.83 mg·h/L acquired for the fasted-state whisky.

3.5. EtOH bioavailability parameters in well-and poor- perfused organs
Table 5 shows the Cmax , tmax , and AUC achieved for EtOH in different organs of
healthy human Caucasian population after ingestion of alcoholic beverages. In this
table, the EtOH bioavailability parameters were obtained using the Simcyp® model for
well-perfused organs (e.g., gut, liver, lung, heart, and kidney) and poor-perfused
tissues (e.g., skin, muscle, and brain). Based on the results, the highest and lowest
EtOH Cmax were acquired for liver and muscle tissues, respectively.
Fig. 7 shows the concentration-time profile of EtOH in liver- gut-brain axis after
ingestion of three alcoholic beverages. Fig. 7a and b) show EtOH concentration-time
profile in liver for fast- and fed-state, respectively. Higher Cmax for EtOH in fastedstate was mentioned compare to that in fed-state. Fed-state EtOH Tmax was later than
that in fasted-state. However, AUC drastically decreased in the case of fed-state.
EtOH concentration-time profile in gut for fast- (Fig. 7c) and fed-state (Fig. 7d)
conditions are illustrated. Higher Cmax for EtOH in fasted-state was observed compare
to that in fed-state. According to the graphs, the elimination phase of EtOH in fedstate was slower than that in fasted-state. AUC of EtOH in gut tissue decreased in fed-
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state compare to the fasted-state. Cmax , Tmax , and AUC of EtOH in brain were depicted
in fasted-(Fig. 7e) and fed-state (Fig. 7f). EtOH concentration-time profile in brain
found to be close to the profile presented for gut tissue. As indicated in Fig. 7e and f,
brains EtOH Cmax , Tmax , and AUC in fasted-state were higher than that in fed-state.

4. Discussion
Physiologic properties of human GI tract greatly affect the intragastric EtOH
concentration.

The observed mean EtOH concentrations were approximately two

times overestimated by the predicted gastric EtOH concentration.

However, the

difference between predicted and observed concentration values became smaller in
fed-state compared to the fasted condition. The underestimation of residual gastric
volume could be responsible for overestimation of EtOH concentration immediately
after drinking in fasted-state.

Meanwhile, according to the fed-state results, the

difference between predicted and observed profiles decreased. The residual gastric
fluid, the volume of liquid meal (fed-state), the gastric emptying time, and gastric
transit time are considered as effective parameters in determining the gastric EtOH
concentration-time profile.

In the presence of meal in fed-state, the gastric fluid

volume will be increased, which results in more EtOH dilution and low gastric
concentration. Lower EtOH concentrations in fed-state compare to the fasted-state
profiles was illustrated in predicted EtOH values. Moreover, it has been found that
gastric emptying time in fed-state is longer than that in fasted-state. That could be the
reason for why higher EtOH concentration in stomach (fed-state) was observed
compare to that in fasted-state. Similarly, the delayed gastric emptying time results in
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delayed duodenal EtOH concentration drop in fed-state compare to that in fasted-state.
The delayed gastric emptying time, elongated EtOH residency in GI tract, and higher
AUC for gastric EtOH in fed-state were explored experimentally by Rubbens et al.,
40

39,

using head space gas chromatography. The C max for duodenal EtOH concentration

was overestimated compared to the observed concentrations. Higher gastric EtOH
concentration enters to the duodenum seems to be responsible for the corresponding
higher EtOH in intestine. Moreover, the catalytic activity of gastric CYP2E1 and
ADH4 could be a reason for why observed EtOH concentration was lower than
predicted values.
The range of EtOH plasma Cmax previously reported in literatures varies from
108.41 mg/L after oral administration of EtOH (150 mg/kg body weight)

22

in fed-

state to 774 mg/L followed by vodka/tonic ingestion (500 mg/kg body weight)

41

in

fasted-state. In addition, various Tmax values were reported in the published articles.
The lowest Tmax was achieved by Levitt et al.,

22

, which was 8.72 min, while the

highest Tmax (62 ± 23 min) was observed by Mitchell et al.,

41

after beer intake. The

extensive gene polymorphism found in ADHs and different experimental designs are
considered as main reasons for the variation in observed plasma EtOH profiles. In our
study, the observed plasma Cmax was underestimated by the predicted value in fastedand fed-state.

One probable reason could be the overestimation of oxidative

metabolism of alcohol in our model.

Particularly, the abundance of ADH

polymorphisms with higher K m values in Causation population might be a reason for
higher observed EtOH concentration in experimental studies.
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The present model provided the possibility to prediction EtOH concentration-time
profile in organ and tissues. Among all organ and tissues, liver showed the highest
Cmax and the lowest Tmax and AUC. That means higher rate and lower extent of EtOH
absorption into the liver compare to the other organs. A probable justification for
these results could be this fact that liver is one of the well-perfused organs and it is the
main organ for EtOH metabolism. Conversely, muscle showed the lowest C max and
highest Tmax . The reason is that muscle is one of the poor-perfused organs. The
predicted EtOH concentration profile in the liver-gut-brain axis illustrated the
significant decrease in EtOH concentrations in fed-state compare to the fasted
condition. The lower concentration of EtOH in fed-state tissues concordant with the
reduced plasma concentration of EtOH after food intake.

5. Conclusion
In the present study, a full PBPK model was developed for EtOH using ADAM
oral absorption model integrated in Simcyp Simulator®. Three alcoholic beverages
including beer (325 mg/kg body weight), wine (300 mg/kg body weight), and whisky
(400 mg/kg body weight) were selected to simulate gastric, duodenal, plasma, and
tissue EtOH concentration-time profiles in fasted- and fed-state. Simcyp modeling
overestimated stomach EtOH Cmax compared to the observed values in fasted-state.
However, increased intragastric fluid in fed-state resulted in predicting closer values to
the observed data. The observed duodenal EtOH concentrations were overestimated
in both fasted- and fed-state. Higher entered EtOH from stomach and the activity of
EtOH metabolizing enzymes in stomach are reasons for EtOH overestimation in
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duodenum. Furthermore, the observed EtOH plasma concentration in both fasted and
fed conditions were underestimated by the predicted values.

Overestimation of

oxidative metabolism of alcohol in our model as well as the ADH polymorphisms in
the studied populations could be responsible for this variation.

Finally, EtOH

concentration-time profile in well- and poorly-perfused tissues was estimated. Liver
and muscle showed the higher and lower rate of EtOH absorption, respectively.
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Table I- 1. Physicochemical properties, physiological/population details, and trial
design for simulating the fasted and fed EtOH PBPK modeling in Simcyp®
Input data to Simcyp® simulator
Fed
Fasted
Reference
Physicoche mical properties
Molecular weight (g/mol)
46.68
Log PO:W
-0.35
Compound type
Neutral
Blood/plasma binding ratio
0.89
KD for HSA (µM)
1000
Absorption model
ADAMa
40
Papp rat intestinal tissue ( × 10-6 cm/S)
56.7 ± 14.8
2
Polar surface area (Å )
20.23
34
Vss (L/Kg)
0.53
Elimination
Enzyme kinetic (Table I2)
physiological/population details
42, 43
Mean gastric emptying time (h)
1.2
0.21
40, 43
Initial volume of stomach fluid (mL)
250
35
Weibull distribution of transit time
2.92 (α) and 4.04 (β)
Simcyp
Mean small intestinal transit time (h)
3.33
Simcyp
Mean colon transit time (h)
12
Simcyp
Trial design and dosing regimen
Population
Human healthy volunteer
No. of trials
5
No. of subjects in trial
5
Minimum age (years)
20
Maximum age (years)
50
Proportion of females
0.5
31
Standard adult body weight (kg)
70
Fluid intake with dose (mL)
500 (beer), 200 (wine), 39, 40
80 (whisky)
Single dose (mg/kg body weight)
325 (beer), 300 (wine), 39, 40
400 (whisky)
22
Proportion of dose inhaled (%)
15
a
ADAM: advanced dissolution absorption and metabolism, LogP O:W (octanol:water
partition coefficient), α and β are scale and shape parameters in Weibull distribution,
respectively. Papp : apparent permeability, K D: dissociation constant of the EtOHprotein complex, HAS: human serum albumin.
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Table I- 2. Michaelis-Menten kinetic parameters for the involved enzymes in EtOH
oxidation
Enzyme
Km (mM)
Vmax (min-1 )
Tissue
Reference
distribution
14-16
ADH1A
4
30
L
14-16, 44
ADH1B*1
0.05
4
L
14, 16
ADH1B*2
0.9
350
L
14, 16
ADH1B*3
40
300
L
14, 16
ADH1C*1
1
90
L, S, D, J
14, 16
ADH1C*2
0.6, 0.05
40
L, S, D, J
14, 16
ADH4
30
20
L, S
ADH5
1000
100
K
ADH6
–
L, S
14, 16
ADH7
30
1800
S, E
a
14, 16
CYP2E1
10
23
L
Abbreviations: Km (Michaelis-Menten constant), Vmax (maximum rate of enzymatic
reaction at saturating EtOH concentration), ADH (alcohol dehydrogenase), L (Liver),
S (stomach), D (duodenum), J (jejunum), K (kidney), E (esophagus), and CYP2E1
(cytochrome P450 2E1).
a
CYP2E1 is upregulated in upper GI tract in chronic alcohol users. 17, 45, 46
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Table I- 3. Key bioavailability parameters (Cmax , Tmax, and AUC) of EtOH in stomach
and duodenum simulated by Simcyp®
Alcoholic beverage EtOH
Fasted-state
Fed-state
dose
(mg/kg
body
weight)
Beer
Stomach Duodenum Stomach Duodenum
Cmax (g/L)
325
41.99
29.76
27.69
16.67
Tmax (min)
0
5.42
0
10.90
AUC 0-180 (g·min/L)
1764.15
1067.86
3250.34 1711.30
Wine
Cmax (g/L)
300
87.02
51.32
41.51
21.86
Tmax (min)
0
5.44
0
12.70
AUC 0-180 (g·min/L)
2873.35
1648.41
4270.11 2087.01
Whisky
Cmax (g/L)
400
232.62
108.22
74.80
35.47
Tmax (min)
0
7.21
0
12.71
AUC 0-180 (g·min/L)
6053.86
3051.01
6985.33 3230.38
Abbreviation: Cmax (the highest concentration), Tmax (time needed to reach Cmax ), and
AUC (area under the concentration-time curve. AUC was calculated according to
trapezoidal rule using Excel® software.
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Table I- 4. Key bioavailability parameters (Cmax , Tmax , and AUC) of EtOH in plasma
simulated by Simcyp®
Alcoholic beverage
EtOH
dose Fasted-state
Fed-state
(mg/kg
body
weight)
Beer
Cmax (mg/L)
325
123.24
27.05
Tmax (min)
25.24
34.37
AUC 0-∞(mg·h/L)
123.31
43.83
Wine
Cmax (mg/L)
300
101.88
22.64
Tmax (min)
23.56
34.25
AUC 0-∞ (mg·h/L)
102.06
37.46
Whisky
Cmax (mg/L)
400
197.60
43.86
Tmax (min)
25.28
37.82
AUC 0-∞ (mg·h/L)
201.83
68.48
Abbreviation: Cmax (the highest concentration), Tmax (time needed to reach Cmax ), and
AUC (area under the concentration-time curve. AUC was calculated according to
trapezoidal rule using Excel® software.
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Table I- 5. The kinetic parameters (Cmax , tmax , and AUC) of EtOH simulated in different organs using Simcyp®.

Alcoholic
beverage

EtOH dose
(mg/kg body
weight)

Fasted/f ed-state

Fasted

B eer

Fasted

G ut

B rain

Kidney

Pancreas

Spleen

Skin

Heart

Muscle

Lung

Cmax

149.74

97.75

108.05

104.97

104.59

105.41

84.02

100.68

62.01

106.61

t max

0.33

0.42

0.45

0.42

0.45

0.42

0.54

0.42

0.75

0.42

AUC

73.95

100.95

112.55

107.95

108.55

108.87

99.07

104.11

103.75

109.71

Cmax

19.09

24.09

26.74

25.78

25.84

26.98

22.45

24.82

18.61

26.23

t max

0.51

0.57

0.6

0.54

0.57

0.57

0.69

0.57

0.96

0.54

AUC

17.47

40.19

44.85

43.01

43.26

43.38

39.45

41.49

41.19

43.67

Cmax

123.28

81.47

89.77

87.33

86.97

87.81

70.48

83.89

51.28

88.79

t max

0.3

0.42

0.45

0.42

0.42

0.42

0.54

0.42

0.75

0.39

AUC

59.04

84.33

94.02

90.17

90.68

90.95

82.74

86.97

86.61

91.63

Cmax

15.24

20.57

22.83

22.01

22.06

22.17

19.15

21.18

15.84

22.37

t max

0.51

0.54

0.57

0.54

0.57

0.54

0.69

0.54

0.96

0.54

AUC

13.95

34.84

38.88

37.28

37.51

37.61

34.21

35.97

35.71

37.86

Cmax

241.86

154.84

171.22

165.97

165.61

166.91

136.27

159.48

100.86

168.75

t max

0.33

0.45

0.48

0.45

0.48

0.45

0.57

0.45

0.81

0.42

AUC

130.33

161.97

180.58

173.19

174.17

174.68

158.99

167.05

166.56

176.04

Cmax

33.95

37.33

41.45

39.93

40.04

40.24

34.88

38.45

29.16

40.61

t max

0.57

0.63

0.66

0.63

0.63

0.63

0.75

0.63

1.02

0.6

AUC

32.16

60.45

67.41

64.64

65.01

65.21

59.31

62.36

61.96

65.65
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300
Fed

Fasted

Whisky

Liver

325
Fed

Wine

Tissues

Mean
pharmacokineti
c parameters

400
Fed

Maximum concentration of EtOH (Cmax , mg/L), time to reach Cmax (tmax , h), and area under the concentration-time curve
(AUC, mg·h/L) after ingestion of three common alcoholic beverages (beer 500 mL, wine 200 mL, and whisky 80 mL)
during 6 h. *Cmax of EtOH in liver after intake of alcoholic beverages in fasted-state was higher than the other organs.
However, it was not statistically significant compared to all other organs (data were not shown).

Figure. I-1

Figure I- 1. Schematic illustration of ethanol (EtOH) destination in human body after
ingestion of alcoholic beverages.
a) EtOH is oxidized to acetaldehyde in hepatocytes through alcohol dehydrogenases
(ADH1A, ADH1B*1, ADH1C*1, ADH1C*2, and ADH4) and cytochrome P450 2E1
(CYP2E1). Reactive oxygen species (ROS) are generated due to the interference of
EtOH with electron transport complexes in mitochondrial membrane. Acetaldehyde is
converted to acetate by aldehyde dehydrogenases (ALDH1/2). b) Acetate is
metabolized to acetyl CoA, which considered as an important metabolic intermediate
of tricarboxylic acid (TCA) and β-oxidation of fatty acids. c) Citrate could be
converted to acetyl CoA by ATP citrate lyase (ACL). The generated acetyl CoA may
result in DNA acetylating or involve in fatty acyl CoA production. d) Fatty acyl CoA
is associated with lipogenesis reactions, which results in triglycerides, very lowdensity lipoproteins (VLDL) and finally alcoholic fatty liver in chronic alcoholic
patients. The excess amount of EtOH in chronic alcoholic patients may result in
elevated acetate in blood, lactic acidemia, and hyperlipidemia.
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Figure I-2

Figure I- 2. A whole-body physiologically based pharmacokinetic model (PBPK)
suggested for EtOH consumption.
Abbreviation: Duoent (duodenum), Jejent (jejunum), Ilent (ileum), CA (arterial blood
concentration), C V (venous blood concentration), Q Tot (total cardiac output), Q hp
(blood flow perfusing the hepatic portal vein), R (tissue-to-blood partition coefficient),
Clint, H (hepatic intrinsic clearance), b (brain), h (heart), li (liver), sp (spleen), lu
(lungs), kd (kidney) f (fat), sk (skin), sa (saliva), and m (muscle).
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Figure I-3
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Figure I-3. EtOH concentration-time profile in stomach after ingestion of different
alcoholic beverages.
a) beer- fast, b) beer- fed, c) wine- fast, d) wine-fed, e) whisky-fast, and f) whisky- fed
states. The EtOH doses for beer, wine, and whisky were 325, 300, and 400 mg/kg
body weight. The standard human body weight was considered as 70 kg. The
Simcyp® data were compared with the experimental data reported by Rubbens et al
[38, 39], while the numerical data points were visualized using Plot Digitizer
(http://plotdigitizer.sourceforge.net).
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Figure I- 4
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Figure I- 4. Duodenal EtOH concentration-time profile after ingestion of different
alcoholic beverages.
a) beer- fast, b) beer- fed, c) wine- fast, d) wine-fed, e) whisky-fast, and f) whisky- fed
states. The EtOH doses for beer, wine, and whisky were 325, 300, and 400 mg/kg
body weight. The average body weight for healthy human was considered as 70 kg.
The Simcyp® data were compared with the experimental data reported by Rubbens et
al, while the numerical data points were visualized using Plot Digitizer
(http://plotdigitizer.sourceforge.net).
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Figure I- 5. The Simcyp® simulation results for regional distribution of EtOH
fraction dose absorbed (Fabs ) and metabolized (Fmet ).
(a beer-Fabs, b) beer-Fmet , c) wine-Fabs, d) wine-Fmet , e) whisky-Fabs, and f) whiskyFmet . Data are shown as Mean ± Standard Error of Mean (Mean ± SEM).

Figure I- 6
b)
300

250

250

EtOH concentration (mg/L)

EtOH concentration (mg/L)

a)
300

200

150

100

50

200

150

100

50

0

0
0

50

100

150

200

0

Time (min)

50

100

150

Time (min)
Beer (Simcyp)
Wine (Simcyp)
Whisky (Simcyp)
Levitte et al., [22]

Figure I- 6. The Simcyp® simulation results for EtOH plasma concentration-time
profiles.
a) fasted- and b) fed-state. The EtOH doses for beer, wine, and whisky were 325, 300,
and 400 mg/kg body weight. The average human body weight was considered as 70
kg. The experimental values for systemic plasma concentration of EtOH were adopted
from
Levitt
et
al.,
[22]
and
visualized
using
Plot
Digitizer
(http://plotdigitizer.sourceforge.net). The amount of EtOH in their study, which was
administered orally, was 150 mg/kg body weight.
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Figure I- 7. The Simcyp® simulation results for EtOH concentration-time profile in
tissues.
a) liver- fast, b) liver-fed, c) gut- fast, d) gut-fed, e) brain- fast, and f) brain- fed states.
The EtOH doses for beer, wine, and whisky were 325, 300, and 400 mg/kg body
weight. The average human body weight was considered as 70 kg. Data are shown as
mean ± standard error of mean (Mean ± SEM).
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ABSTRACT
In this study, the effect of clinically relevant ethanol (EtOH) concentrations on the
expression and functionality of P- glycoprotein (P-gp) was explored in Caco-2 cell
monolayer. EtOH did not show significant alteration in cell viability at concentrations
found in GI tract. To investigate the EtOH effect on P-gp, expression of P-gp was
induced by treating normal cells with vinblastine (10 nM). Immunofluorescent (IF)
images of normal and P-gp induced Caco-2 showed that the abundance of P-gp
decreased by increasing EtOH concentration and treatment time. Moreover, the effect
of EtOH on abundance of xenobiotic transporters in normal and P-gp induced Caco-2
cells was analyzed. Sequential Windowed data independent Acquisition of the Total
High-resolution Mass Spectra (SWATH-MS) proteomics approach showed that the
abundance of P-gp polypeptides was diminished after treatment of normal and P-gp
induced Caco-2 cells with EtOH for 4 and 24 h. Moreover, Calcein-AM assay showed
that by increasing the time and concentration of EtOH, the efflux activity of P-gp was
reduced in P-gp induced Caco-2 cells.

Furthermore, EtOH effect on transport

parameters of talinolol (Tal, a P-gp substrate) and PF-5190457 (PF-57), an alcohol
craving treatment currently undergoing clinical trials) were investigated in the
presence and absence of verapamil (P- gp inhibitor). According to the results, EtOH
showed significant decrease in efflux ratio (ER) of Tal in Caco-2-treated cells with 50
mM EtOH for 24 h in the presence of verapamil. However, EtOH did not show
significant effect on ER of PF-57 in the presence or absence of verapamil.
KEYWORDS: Ethanol, Caco-2 cell monolayer, P-glycoprotein, SWATH-MS
proteomics, Talinolol transport, Calcein- AM assay
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INTRODUCTION
The effect of drinking alcohol on drug absorption and bioavailability has received
considerable attention during recent years.1,

2

Ethanol (EtOH) alters the body

exposure to the extended-release drug formulations through induction of dose
dumping.3-5 Hence, US Food and Drug Administration (FDA) has recommended to
characterize the effect of alcohol on drug release profile.6 Furthermore, EtOH affects
the pharmacokinetic and pharmacodynamic of medication such as, ezogabine,7
elvitegravir,8 and opioids9 in alcoholic patients. Acute EtOH consumption primarily
affects the rate and extent of drug absorption10 and to a lesser extend drug clearance.11
Hence, estimation of EtOH interaction with the involved absorption mechanisms in
gastrointestinal (GI) tract is beneficial to understand how EtOH alters the disposition
of oral drugs.
The human colorectal adenocarcinoma cell line Caco-2 is widely used as a
standard model for human intestinal epithelium to assess drug permeation and
transport mechanisms.12, 13 Caco-2 monolayer has been broadly used to study all four
possible drug transport pathways across epithelial cells including passive transcellular,
paracellular, carrier mediated routes, and transcytosis.14, 15 One of the most abundant
transporters in Caco-2 cell line and human GI tract that plays an important role in
drugs absorption and disposition, is permeability-glycoprotein (P-gp).
P-gp, also known as multi drug resistant protein-1 (MDR-1), is a 170 kDa
transmembrane efflux transporter encoded by ATP-binding cassette (ABC)
superfamily.16-18

P-gp (ABCB1) is the most extensively studied transporter in

mammalian that was first discovered in colchicine-resistant Chinese hamster ovary
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cells.19 In human, P-gp is expressed on the apical side of GI epithelial cells, the apical
side of epithelial cells in proximal tubules of kidney, the apical surface of epithelium
in placenta, the biliary canalicular membrane of hepatocytes in liver, and endothelial
cells in blood brain barrier (BBB).20

Intestinal P-gp plays a significant role in

absorption and disposition of a wide variety of drugs by limiting their cellular uptake
from intestinal lumen into the enterocytes. Consequently, the functionality of P-gp
and its expression level greatly influence the pharmacokinetic, safety, and efficacy
profiles of drugs.
The expression of P-gp has been extensively investigated at mRNA and protein
levels.21,

22

While, the mRNA level of P-gp does not necessarily translate into the

amount of expressed protein,23 the quantification of protein seems to be more reliable
approach for P- gp expression assessment.24, 25 Enzyme- linked Immunosorbent Assay
(ELISA),26 flow cytometry,27 and immunoblotting (Western blotting)28 methods are
the most well-known methods for identification and quantification of P-gp and other
transporters.

However, those methods suffer from some limitations such as, low

throughput performance, intensive laboring, applying expensive antibodies, and low
specificity. Mass spectrometry (MS), which avoids a vast majority of those flaws, has
gained a great demand in protein studies.29-31

Among all MS-based proteomics

methods, the Sequential Windowed data independent Acquisition of the Total Highresolution Mass Spectra (SWATH-MS) offers superior advantages, like high accuracy
and reproducibility over the other MS approaches.32
Transport behavior of P-gp substrates across Caco-2 cell monolayer is broadly
used by pharmaceutical industries to measure human intestinal P- gp activity.33,

37
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Caco-2 cell monolayer transport assay is considered as a well-established method to
determine if a compound is substrate, inhibitor or both for P- gp. While, P-gp is
expressed in various organs (e.g., GI tract, BBB, liver, and kidney), inhibition of P-gp
greatly affect the pharmacokinetic and efficacy of P-gp substrates. Consequently,
inhibition of P-gp in GI tract increases the oral absorption of drugs that are P-gp
substrate. Elevated plasma concentration of drugs with narrow therapeutic index can
cause severe toxicity. Therefore, dose adjustment is needed for P-gp substrates once
they are co-administered with a P-gp inhibitor.
In addition to Caco-2 monolayer transport assay, fluorescent probe efflux assay
can also be used to evaluate P-gp functionality. Calcein-acetoxymethylester (calceinAM) is a non-fluorescent P-gp substrate that cleaves by intracellular esterases to form
fluorescent impermeable calcein.35,

36

This method is widely used as a high-

throughput, facile, and real- time P-gp inhibition assay.37
In the present study, the effect of EtOH on expression and functionality of P- gp in
normal and P-gp induced Caco-2 cell monolayer was analyzed. EtOH cytotoxicity in
Caco-2 cells was examined and immunohistochemistry staining was used to visualize
the expressed P-gp on the Caco-2 cell membrane. Moreover, SWATH-MS proteomics
approach was used to find out if EtOH can alter the expression level of P-gp in Caco-2
cell monolayer. Furthermore, the transport behavior of talinolol (Tal, β1 -antaginist)
and PF-5190457 (PF-57, a ghrelin reverse agonist), as two model drugs, was
investigated to find out the effect of EtOH P-gp activity. Finally, the Calcein- AM
fluorescent assay was conducted to prove the effect of EtOH on P-gp efflux
functionality.
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EXPERIMENTAL SECTION
Che mical and Reagents.

Molecular

biology

grade

EtOH >99.5%,

iodoacetamide (IAA), dithiothreitol (DTT), ammonium bicarbonate, and sodium
deoxycholate were purchased from Sigma Aldrich (St. Louis, MO). Racemic talinolol
(Tal), the internal standard (IS) Tal-d5 and vinblastine sulfate were purchased from
Toronto Research Chemicals (TRC, Toronto, Ontario, Canada).

RPMI 1640,

Dulbecco’s modified Eagle medium (DMEM), fetal bovine serum (FBS), Pierce™
BCA protein assay kit, and Vybrant™ cell adhesion assay kit was obtained from
Thermo Fisher Scientific Inc (Waltham, MA, USA).

ProteoExtract™ Native

Membrane Protein Extraction Kit was obtained from EMD Millipore (Billerica, MA).
WST-1

(2-(4-iodophenyl)-3-(4-nitrophenyl)-5-(2,4-disulfophenyl)-2H-tetrazolium,

monosodium salt) was purchased from Roche (Mannheim, Germany).

Hank's

balanced salt solution (HBSS), penicillin/streptomycin, and trypsin- EDTA (0.25%)
were acquired from the American Type Culture Collection (ATCC, VA, USA).
Optima™ LC-MS/MS grade of acetonitrile, methanol, and formic acid were purchased
from Fisher Scientific (Fair Lawn, NJ, USA). Deionized water was obtained using a
Milli-Q® Synthesis A10 system fitted with a Q-Gard 2 Purification Pack (Millipore,
Bedford, MA, USA).

Proteomics grade trypsin and trypsin-predigested β-

galactosidase (originated from Escherichia coli) were purchased from SCIEX
(Framingham, MA). All other reagents used in this study were of analytical grade.
Cell Culture and EtOH Treatment. Caco-2 cells (ATCC® HTB-37™ , passage
number 50–65) were maintained at 37 °C and grown in 25- ml flasks in an incubator
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with a controlled, humidified atmosphere consisting of 5% CO 2 and 95% air. Cells
were cultured in an enriched medium consists of RPMI-1640, DMEM, FBS and
penicillin/streptomycin in a ratio of 50:35:15:1
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. In order to enhance the expression

of P- gp in Caco-2 cell line, normal Caco-2 cells were treated with 10 nM vinblastine
for 4–5 passages to induce the expression of P-gp and form P-gp- induced Caco-2 cell
line.16,
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The culture medium was changed every second days and cells were

trypsinized by trypsin–EDTA (1%) after reaching 70–80% confluence. Normal and Pgp- induced Caco-2 cells were seeded onto semi-permeable PET filter inserts (Corning
Costar Corporation, Corning, NY) with 6.4 mm diameter, 0.33 cm2 growth area, and
0.4 µm pore size. Each membrane of the 24-transwell permeable insert received 0.2
mL of a 3.2 × 105 cells/mL suspension and 0.6 mL culture medium into the wells.
Caco-2 cells were then grown and differentiated for 21 days. Medium changed every
two days for the first two weeks and then every day until day 21 when a fully
differentiated monolayer had achieved.
To assess the effect of EtOH on Tal transport in mature norm al and P-gp- induced
Caco-2 monolayer, the plates containing transwell inserts were put into chambers
filled with 95% air, 5% CO2 and kept in humid incubator at 37 °C. Various EtOH
concentrations (25, 50, and 100 mM) diluted in culture medium were added to the
both apical and basolateral sides of cells.

In each treatment, the atmosphere of

chambers was saturated by the same concentration of EtOH.
Cytotoxicity Assay. The cytotoxicity of EtOH treatment on the Caco-2 cells was
evaluated according to the colorimetric method using a water-soluble tetrazolium salt
(WST-1). In this method, the cleavage of the tetrazolium salt to formazan by active
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cellular mitochondrial dehydrogenases indicates the viable cells. For this purpose,
Caco-2 cells were seeded at a concentration of 2 × 104 cells/well in a 96-well plate for
2–3 days to achieve 70% confluence. The culture medium was removed and replaced
by different EtOH (0–1000 mM) and placed in the corresponding chambers saturated
with EtOH and AA vapor contained 95% air and 5% CO 2 and placed in incubator.
Clotrimazol was used as a positive control at different concentrations (20, 40, 60, 80,
and 100 µM). Cells were incubated for 24, 48, and 72 h at 37 °C in an incubator with
a controlled atmosphere. At the end of treatment, 10 µl of WST-1 was added to each
well and incubated for 4 h at 37 °C. The absorbance of each well against background
control was measured at 450 nm, while reference wavelength set at 650 nm.
Transepithelial Electrical Resistance (TEER). TEER assay was used as a realtime, non-destructive, and label free method to characterize the quality of the cell
monolayer integrity. TEER of the normal and P-gp- induced Caco-2 cell monolayers
were evaluated by an EVOM2 (World Precision Instruments, Sarasota, FL) equipped
with STX2 “chopstick” silver/silver chloride (Ag/AgCl) electrodes.
TEER assay was performed 21-days post seeding of normal and P-gp induced
Caco-2 cells on filter inserts. TEER measurements were done before starting of EtOH
treatment as well as 4 and 24 h after alcohol exposure to the Caco-2 monolayers. The
relative changes in TEER values before and after EtOH treatments were compared to
that for buffer treatment, as the control group.

TEER values were calculated

according to the following equation:
TEER = (Rmonolayer ‒ Rblank ) × A (Ωcm2 ),
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(2)

where, Rmonolayer is the measured resistance of cell monolayer, Rblank represents the
resistance of filter inserts without cell monolayer, and A is the available filter inserts
surface area.
Immunohistochemistry. Normal and P-gp induced Caco-2 cells were grown on
24-transwell permeable insert for 21-days and the culture media were changed every
two days in the first week and every day in the following 14 days. Then, the cells
were incubated with EtOH to assess the effects of different EtOH concentrations (0,
25, and 50 mM) on the expression of P- gp after 24 h of incubation. Culture medium
containing 25 and 50 mM of EtOH were added to the apical (AP, 200 µL) and
basolateral (BL, 600 µL) sides, respectively. Culture medium containing phosphate
buffered saline (PBS, 50 mM) was applied as negative control. Then, the 24-well
plates containing filter grown Caco-2 cells were placed in the chambers saturated with
the corresponding EtOH concentration and PBS (control). Chambers were kept at 37
°C for 24 h in incubator. At the end of treatments, the culture media were removed
from AP and BL sides and washed three times using PBS. The cells were fixed with
4% formaldehyde for 10 min. Then, the cells were rinsed with PBS and permeabilized
with 0.1% TX-100/PBS for 15–20 min and washed. The monolayer was block with
1% Bovine serum albumin (BSA)/PBS for 45 min followed by incubation with mouse
IgG1 anti- human P-gp primary antibodies (1:10 dilution, Thermo Fisher Scientific,
Waltham, MA, USA) for 60 min at room temperature. The filters were rinsed 3 times
in PBS and then incubated with Cy5-conjugated goat anti- rabbit IgG secondary
antibody (Thermo Fisher Scientific, Waltham, MA, USA) for 60 min at room
temperature in the dark. Then, the secondary antibody was aspirated, and the PET
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bottom of the filter inserts were cut and fixed on glass slides, while the BL side of the
cells facing up the slide. The filters were incubated with VECTASHIELD® antifade
mounting medium with DAPI (Vector Laboratories, catalog number: H-1200, CA,
USA) for 10 min to preserve fluorescence. Finally, slides were imaged on an EVOS
FL Auto fluorescent microscope (Life Technologies; Thermo Fisher Scientific) using
Cy®5 light cube (excitation 628/40 nm; emission 685/40 nm) and DAPI light cube
(excitation 357/44 nm; emission 447/60 nm).
Membrane Protein Extraction and Sample Preparation.

Membrane

associated proteins were extracted from normal and P- gp induced Caco-2 cells using
the ProteoExtract™ Native Membrane Protein Extraction Kit (M-PEK, EMD
Millipore, Billerica, MA). For this purpose, normal and P-gp induced Caco-2 cells
(passage number 55–65) were seeded at the density of 6.5 × 104 cells per each 24-well
PET filter inserts for 15–21 days. By the end of time needed for cell differentiation,
cells were treated with EtOH (25, 50, and 100 mM) and placed in saturated chambers
filled with 95% air, 5% CO 2 for 4 and 24 h and kept in humid incubator at 37 °C. To
obtain membrane associated proteins from filter-grown Caco-2 cells, the attached cells
were scratched by cell scraper from the filter inserts. Then, the cells were incubated in
100 µl of extraction buffer I containing 0.5 µl of protease inhibitor cocktail according
to the protocol supplied by the vendor. The cell suspension was gently shaken for 10
min at 4 °C and the homogenate was centrifuged at 3000 × g for 5 min to separate
soluble proteins from cell pellet.

To extract the membrane proteins, 100 µl of

extraction buffer II containing 0.5 µl of protease inhibitor cocktail was added to the
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cells and shacked at 4 °C for 30 min.

Finally, the enriched homogenate with

membrane bounded proteins was collected from supernatant.
To digest proteins, 100 µL of 1 mg/mL of soluble and membrane bounded
proteins were incubated with 15 µL of dithiothreitol (100 mM) and 50 ml of
ammonium bicarbonate buffer (50 mM, pH 7.4) at 95 °C for 10 min. Afterward, 15
µL of iodoacetamide (150 mM) was added to the mixture and incubated at room
temperature for 30 min in the dark. Ice-cold chloroform extraction solution (0.5 mL)
which contains (MeOH 50%, CHCl3 25%, and water 25%) was added to each sample
and centrifuged at 4 °C for 5 min at 16000 × g. The protein pellet was washed with
ice-cold methanol (250 µL) and resuspended in 46.5 µL of sodium deoxycholate (3%
w/v) solution prepared in ammonium bicarbonate buffer (50 mM, pH 7.4). Then, 3.5
µL of trypsin (1 mg/mL) was added to the latter solution and put in the Barocycler®
2320 EXT (Pressure Biosciences; West Bridgewater, MA) to digest the proteins.
Protein to trypsin ratio was 20:1 (w/w). Barocycler repeated cycles of hydrostatic
pressure at 35000 psi for 90 cycles (90 min) to improve the protein digestion.
Afterwards, 10 µL of 2.5% formic Acid in 1:1 (v/v) mixture of water/acetonitrile was
added to the digest and centrifuged at 10,000 ×g for 5 minutes at 4°C. Finally, 2.5 µL
of β- galactosidase (31.25 pmol), as an external control, was added to the digested
protein solution before injection to LC-MS/MS.
SWATH-MS Analysis.

The SWATH-MS proteomics analysis and data

processing were accomplished based on the previously published method.40,
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Briefly, A SCIEX 5600 TripleTOF mass spectrometer equipped with a DuoSpray ion
source (SCIEX, Concord, Canada) coupled to Acquity UHPLC HClass system
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(Waters Corp., Milford, MA, USA) was used. The mass spectrometer was operated in
positive electrospray ionization (ESI) mode for all the experiments. Compound and
source/gas parameters used in SWATH-MS method were as follows: DP = 120 V, CE
= 10 V, collision energy spread (CES = 5V), TEM = 400 °C, ISVF = 5500 V, GS1 =
55 psi, and GS2 = 60 psi.

TOF masses were collected from m/z 300 to 1500.

SWATH data was acquired in the range of m/z 400 to 1100 over 70 SWATH windows
per cycles with a window size of m/z 10. The total cycle time for SWATH acquisition
was 3.95 sec.
The digested P-gp peptides were separated on an Acquity UHPLC Peptide BEH
C18 (2.1 × 150 mm2 , 300 Å, 1.7 μm) equipped with Acquity VanGuard precolumn
(2.1 × 5 mm2 , 300 Å, 1.7 μm). Autosampler temperature was kept at 10 °C and the
column temperature was maintained at 40 °C during all injections.

The

chromatographic separation was performed with a runtime of 120 min at 100 μL/min
with a gradient method using mobile phase A (98% water, 2% acetonitrile, 0.1%
formic acid) and mobile phase B (98% acetonitrile, 2% water, 0.1% formic acid). A
gradient chromatographic elusion method was performed as follows: 98% A from 0 to
3 min, 60% to 90% A from 3 to 48 min, 20% A held from 49 to 52 min to flush the
column, 98% A at 53 min. The column was equilibrated at 98% A from 53 to 60 min
before the start of next run. The amount of protein per injection on the column was 10
μg. In each batch, trypsin-digested β- galactosidase that is a quality control standard
(1.65 pmol/injection) was injected to each sample to monitor mass calibration of the
TOF detector and normalization of peptides intensity in SWATH label free
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quantification (LFQ) approach. The LFQ was performed using Skyline, which is an
open source application for targeted proteomics quantitative data analysis.
Protein

Quantification.

Membrane

Proteins

and

digested

peptides

concentrations were analyzed using Pierce™ BCA protein assay kit (Thermo Fisher
Scientific, Rockford, IL, USA) and NanoDrop™ 2000 (Thermo Fisher Scientific,
Wilmington, USA) by measuring UV-vis absorbance at wavelengths of 562 and 280
nm, respectively. Protease- free bovine serum albumin (BSA) solutions (125–2000
µg/mL) were used as the standard calibration line for the BCA protein quantification
method.
Calcein-AM Functional Assay. Vybrant™ multi-drug resistance kit (Thermo
Fisher Scientific, MA, USA) was used to measure the effect of different EtOH
concentrations on the efflux properties of ABCB1 in P-gp induced Caco-2 cells. In
this assay, the fluorogenic dye calcein- AM was used as a substrate for efflux activity
of ABCB1 transporter in P-gp induced Caco-2 cells after 4 and 24 h of treatments with
EtOH.

Calcein-AM is a lipophilic ester that easily enters cells through passive

diffusion.

Inside the cells, cytoplasmic hydrolases can convert non-fluorescent

calcein-AM to fluorescent calcein. Both compounds are well retained in cytosol,
however, P-gp induced Caco-2 cells can rapidly extrude calcein-AM out of the cells
and decrease the accumulation of fluorescent calcein in the cytosol.

The higher

fluorescent yield of cells reflects the lower activity of P-gp to efflux calcein-AM out
of the cells. In this method, P- gp induced Caco-2 cells (5.0 × 104 cells/each well,
passage number 55–65) were seeded on CELLSTAR black, clear-bottom 96-well plate
(Grenier, #M0562) for 2–3 days prior to EtOH treatment. Then, cells were incubated
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with different EtOH concentrations (25, 50, and 100 mM) in culture medium as well
as negative control group (100 mM PBS, pH 7.4) for 4 and 24 h. On the day of
experiment, medium containing EtOH and PBS were aspirated from the cells and then
100 µL of calcein- AM solution in culture medium (1 µM) was added to each well and
incubated at 37 °C for 30 min.

Afterwards, the cells in plate were washed and

centrifuged (400 × g) twice with 200 µl cold RPMI1640 culture medium. Finally, a
Molecular Device SpectraMax® M 5 plate reader (Molecular Devices, Sunnyvale, CA)
was used to measure the fluorescence intensity
Chromatographic Conditions

and Triple

Quadruple

Tande m Mass

Spectrometry. Chromatographic detection of Tal and PF-57 were performed using an
Acquity UPLC BEH C18 (2.1 mm × 50 mm) with 5 μm particle size and 130 Å pore
size analytical column (Waters Corp, Milford, MA). The column was maintained at
45 °C and auto-sampler temperature was kept at 10 °C. A gradient elution method
was applied with a mobile phase consisting of water containing 0.1 % formic acid
(solvent A) and 100 % acetonitrile containing 0.1 % formic acid (solvent B). The flow
rate was set at 0.4 mL/min. Each chromatographic cycle for Tal initiated at 90 %
solvent (A), which gradually decreased to 70 and 20% over 0.5 and 1 min,
respectively. The solvent proportion maintained at this condition until 1.25 min. To
re-equilibrate the column for the next run, the proportion of solvent (A) was increased
gradually to 70 and 90% at 1.5 and 2 min and maintained constant until the end of the
run at 2.5 min. The retention time for Tal was 1.07 min.
Mass spectral detection of positive ions in MRM mode was performed using an
API 3200 LC-MS/MS quadrupole tandem mass spectrometer (Applied Biosystems/
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MDS Sciex Inc., Ontario, Canada).

The 268.2 → 116.1 m/z MRM transition

(precursor → product ions) was chosen for Tal. Compound and source/gas parameters
used for ESI-positive modes of Tal were as follow; declustering potential (DP = 50
V), entrance potential (EP = 10 V), collision cell entrance potential (CEP = 12 V),
collision energy (CE = 34 V), cell exit potential (CXP = 3 V), curtain gas (CUR = 10
psi), collision gas (CAD = 5 psi), ion spray voltage floating (ISVF = 5500 V),
temperature (TEM = 500 °C), nebulizer gas (GS1 = 10 psi), and turbo gas (GS2 = 10
psi). The chromatographic and mass spectral conditions for PF-57 were optimized
according to our published literature, previously42 .
Drug Transport Studies. Normal and P-gp- induced Caco-2 monolayers were
used for transport experiments 21-days post seeding on Transwell inserts.

All

experiments were conducted at 37 °C under laminar airflow. To assess the effect of
EtOH on Tal transport in normal and P-gp-induced Caco-2 monolayer, the plates
containing transwell inserts were put into chambers filled with 95% air, 5% CO 2 and
kept in humid incubator at 37 °C. Various EtOH concentrations (25, 50, and 100 mM)
diluted in culture medium were added to the both AP and BL sides of cells. Culture
medium containing PBS was applied as negative control (0 mM EtOH). In each
treatment, the atmosphere of chambers was saturated by the same concentration of
EtOH or buffer (for negative control).
Prior to the transport experiments, cells were washed twice with PBS and
preincubated with HBSS supplemented with 25 mM HEPES (pH 7.4 and 6.5) for 30
min. Tal was added to the AP and BL compartments of the monolayer at a final
concentration of 5 µM in HBSS-HEPES buffer.
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The AP and BL sides of the

monolayer contained 0.2 and 0.6 ml of the transition buffer, respectively. All transport
analyses were conducted in the AP to BL (AP-BL) and BL to AP (BL-AP) direction of
the monolayer. After 4 h of transport, 100 µl of samples were withdrawn from the AP
and BL sides of the monolayer and replaced with an equal amount of fresh transition
buffer.

The collected samples were analyzed using the previously described LC-

MS/MS methods for Tal.
Apparent permeability coefficient (Papp ) of Tal was calculated according to the
following equation:

Papp =

dM r
1
,
×
dt
A × C D (0)

(3)

where, A stands for surface area of the cell monolayer (0.33 cm2 ), CD (0) is the
initial concentration of the drug added to the donor compartment, t is the time of
transport, Mr represents the mass of compound in the receiver side, and dMr /dt
accounts for the flux of the drug across the cell monolayer. Uptake ratio (UR) and
efflux ratio (ER) were obtained as below;
𝑃𝑃

(4)

𝑃𝑃

(5)

UR = 𝑃𝑃app (AP-BL)
app (BL-AP)
ER = 𝑃𝑃app (BL-AP)
app (AP-BL)

where, Papp (AP-BL) and Papp (BL-AP) stand for apparent permeability from AP to BL
and BL to AP sides, respectively.
2.8. Statistical Analysis. Results are reported as Mean ± Standard Error of Mean
(SEM) from three independent experiments unless otherwise mentioned.

The

normality of data sets in each experiment was checked with Shapiro-Wilks test. One49

way analysis of variance (ANOVA) with Dunnett's T3 post hoc test (SPSS 23, SPSS,
Inc.) was used for normally distributed observations.

Kruskal-Wallis one-way

ANOVA (non-parametric ANOVA) with Dunn's multiple comparison post hoc test
was used for non- normally distributed data. In all analyses, probability values <0.05
was considered significant.

RESULTS
WST-1 Cytotoxicity. Normal Caco-2 cells were examined by WST-1 assay to
determine the EtOH- induced cytotoxicity. EtOH and buffer exposure experiments
showed that alcohol cytotoxicity was increased in a time- and EtOH concentrationdependent manner (Figure 1). According to Figure 1, the viability% of Caco-2 cells
was reduced by increasing EtOH treatment time from 24 to 72 h. Moreover, by
increasing EtOH concentration from 0 to 1000 mM, the cell viability was decreased,
accordingly. Figure 1 shows that after 72 h of treatment, the viability of Caco-2 cells
was decreased to 85, 78, and 47% at EtOH concentrations of 250, 500, and 1000 mM,
respectively. In the case of buffer treatment, cell viability was 85% in 1000 mM
buffer-treated group after 72 h treatment (Figure. 1). Treatment of Caco-2 cells with
the positive control (clotrimazole, 100 µM) reduced the viability to 80.4 ± 9.0, 75.4 ±
2.3, and 17.9 ± 3.4 % after 24, 48, and 72 h of treatment, respectively. Results showed
that at EtOH concentration < 500 mM, which is more clinically relevant, no
significant cytotoxicity is induced by EtOH compared to the control group (buffertreated cells).
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TEER Assay. The TEER was evaluated for the normal and P-gp induced Caco-2
cell monolayers after EtOH treatments to show the effect of EtOH on the integrity of
junctional proteins. Figure 2 illustrates the comparison of TEER values measured for
normal and P-gp induced Caco-2 cells after 4 and 24 h of treatment with 50 mM
EtOH. According to the results, P-gp induced cells showed significantly higher TEER
values compared to the normal cells (Figure 2). In addition, a significant decrease in
TEER values was observed for the EtOH-treated normal and P-gp induced Caco-2
cells compared to the buffer-treated cells. Figure 2 shows that the TEER values of
normal Caco-2 cells was decreased after 4 h of treatment with EtOH compared to the
buffer-treated (P-value = 0.001) cells. Similarly, a reduction in TEER value was
observed for the P-gp induced cells compare to the buffer-treated cells after 4 h of
treatment (P-value = 0.05).

Furthermore, the TEER values of normal and P-gp

induced Caco-2 cells was drastically decreased (P-value = <0.001) after 24 h of
treatment with EtOH (50 mM) compared to the control group. The reduction in TEER
values in the presence of EtOH evident the effect of EtOH on the integrity of Caco-2
cells. This may arise from the effect of EtOH on the organization of paracellular
proteins.
Immunohistochemistry.

Figure 3 shows the immunofluorescent (IF)

microscope images of P- gp protein in normal (Figure 3a, c, and e) and P-gp induced
(Figure 3b, d, and f) Caco-2 cells after buffer (Figure 3a and b) and EtOH (Figure
3c-f) treatments for 24 h. The higher expression level of P-gp proteins in the P-gp
induced Caco-2 cells are clearly mentioned in IF images. In the absence of EtOH, no
clear sign of P-gp was observed in normal Caco-2 cells (Figure 3a), while the
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localization of P-gp is clearly mentioned in P-gp- induced cells by monoclonal P-gp
antibody (Figure 3b). Figure 3c and d show the normal and P-gp- induced cells after
24 h of treatment with EtOH (25 mM). There is no change in the appearance of
normal and P-gp- induced cells after treatment with 25 mM EtOH.

However, by

increasing EtOH concentration to 50 mM, a clear decrease in the number of cells with
distinct P-gp localization was observed (Figure 3f).
SWATH-MS.

Two

P-gp

digested

peptides

including

K.LVTMQTAGNEVELENAADESK.S and K.GTQLSGGQK.Q were recognized and
normalized according to the trypsin digested β-galactosidase intensity and total protein
content. The cellular position of each peptide has been shown in Figure 4. Table 2
shows the abundance of six efflux transporters in 25, 50, and 100 mM EtOH-treated
cells to the control group. According to the results, no significant difference was
observed in the abundance of P-gp in control versus EtOH treated normal Caco-2 cells
after 4 and 24 h of treatment (Table 2). Similarly, MRP-2, MRP-3, and MRP-4
showed signs of reduced expression in EtOH-treated groups versus control (Table 2).
Calcein-AM Functional Assay.

To investigate the effect of EtOH on the

functionality of P-gp, Calcein-AM assay was conducted to ensure the remained
fluorescent yield of calcein inside the cells. Figure 5 shows the relative fluorescent
yield of calcein remained inside the P-gp induced Caco-2 cells after 4 and 24 h
treatment with different EtOH concentrations (0–100 mM). Results indicated that the
functionality of P-gp was decreased after treatment of cells with EtOH for 4 and 24 h.
According to Figure 5, after (4 h) treatment of P- gp induced cells with 25 mM EtOH,
the fluorescent yield of calcein was 29.3 ± 14.05% higher than that in control group.

52

Meanwhile, the calcein fluorescent yield was 49.5 ± 10.3% higher than that in buffertreated cells after 24 h of incubation with EtOH (Figure 5). The fluorescent yield of
calcein at higher EtOH concentrations (50 and 100 mM) was not dramatically changed
compare to the 25 mM. It suggests that at 25 mM concentration, the inhibitory effect
of EtOH on P-gp was nearly saturated and increased EtOH concentration did not
further affect the P-gp functionality.
Tal and PF-57 Transport. To evaluate the functionality of P-gp in normal and
P-gp induced Caco-2 cells, Tal and PF-57 transport assays were conducted in the
presence and absence of P-gp inhibitor (verapamil, 200 µM). Papp (AP-BL) and Papp (BLAP)

as well as UR and ER were measured for Tal and results are shown in Table 1. No

significant difference was observed in Tal Papp

(AP-BL) ,

Papp

(BL-AP) ,

normal Caco-2 cells in the presence and absence of verapamil.

UR, and ER in
However, in the

presence of verapamil, Tal Papp (BL-AP) and ER in P- gp induced Caco-2 cells were lower
than that in absence of verapamil. Similarly, there was no difference in ER of PF-57
in the presence and absence of verapamil (ER <2). According to the Table 1, the ER
of PF-57 in P- gp induced Caco-2 cells was 7.1 ± 0.6 (ER>2) that proves PF-57 is a Pgp substrate. The ER of PF-57 was dropped to 1.7 ± 0.1 in the presence of verapamil.
Figure 6a and b show the ER of Tal and PF-57 in the presence and absence of
verapamil (200 µg/mL), respectively. In these experiments, the P-gp induce Caco-2
cells were treated with different EtOH concentrations (0–100 mM) for 24 h. Results
show that ER of Tal and PF-57 was significantly (P = 0.002) decreased in the presence
of verapamil (Figure 6a and b). Moreover, P-gp induced Caco-2 cells treated with 50
mM EtOH showed significant decrease in ER of Tal in the presence of P-gp inhibitor

53

(P = 0.04) compare to the control group. Further, the ER of PF-57 did not show any
significant changes by increasing EtOH concentration (Figure 6b).

DISCUSSION
The mitochondrial toxicity of alcohol was examined after 24, 48, and 72 h
treatment of Caco-2 cells with different EtOH concentrations. Results showed that no
significant cell toxicity was induced by EtOH at clinically relevant concentrations in
GI tract. Rubbens et al has reported the EtOH concentrations in human GI tract after
ingestion of common alcoholic beverages.43, 44 They have shown that the maximum
duodenal concentration of EtOH after beer (500 mL, 866 mM), wine (200 mL, 1832
mM), and whisky (80 mL, 6662 mM) intake was 233, 233, and 300 mM,
respectively.44

According to our results and the experimentally measured EtOH

concentrations, no significant cell toxicity is expected to be arisen from drinking
alcohol in human GI tract.
To investigate the effect of drinking alcohol on the expression and functionality of
P-gp, vinblastine was used to induce the expression of P-gp in Caco-2 cells.45
Shirsaka and co-workers had previously explored that the mRNA level of P-gp in P-gp
induced Caco-2 cells (vinblastine- induced cells) is approximately five times higher
than that in normal Caco-2 cells.46 Moreover, the increased expression level of P-gp
was reported in other works at mRNA and protein levels.39,

47, 48

In our study, the

effect of vinblastine on paracellular integrity of P-gp induced Caco-2 cells was
compared to the normal cells before and after EtOH treatment. Comparison of TEER
values in normal and P-gp induced Caco-2 cells clearly showed that the integrity of
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vinblastine- induced Caco-2 cell was enhanced compared to the normal cells. The
higher TEER for vinblastine- induced Caco-2 cell versus normal cells was comparable
to the previously reported data.49 Furthermore, in both normal and P-gp induced
Caco-2 cells, EtOH treatments resulted in decreased paracellular integrity and
lowering TEER values compared to the control. The reduction in TEER values by
EtOH and its major metabolite acetaldehyde in Caco-2 cells was extensively reported,
previously.50-53
To visualize the expression of P-gp in normal and P-gp induced Caco-2 cells, the
IF images of normal and P-gp induced Caco-2 cells were compared before and after
EtOH treatment. Immunohistochemistry studies of normal and P-gp induced Caco-2
cells illustrated the higher expression of P-gp in P-gp induced Caco-2 cells compare to
the normal cells. Moreover, EtOH treatment studied showed that increasing EtOH
concentration from 25 to 50 mM resulted in decreased expression of P-gp.

The

disappearance of red color (indicated for P-gp) around the DAPI stained nuclei
mentioned the reduction of P-gp expression.
SWATH-MS proteomics was used to verify any probable changes induced by
EtOH (50 mM) in the expression of P-gp peptides. According to the obtained results,
the expression level of the most efflux transporters including MDR-1, MRP-2, MRP3, and MRP-4 were decreased in EtOH-treated P- gp induced Caco-2 cells but not
significantly. The role of EtOH in molecular induction or inhibition of transporters
might be helpful to describe the EtOH effects on transporters expression. Geick and
co-workers has investigated for the first time that nuclear receptor PXR (pregnane X
receptor) is involved in xenobiotic induction of MDR-1.54 More recently, Choi and
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coworkers has shown that chronic EtOH ingestion significantly upregulated hepatic
Pxr and constitutive androstane activated receptor (car) mRNA expression in binge
mice models55 . According to the current study and the previous findings about EtOH
effects on the induction of P-gp, it could be hypothesized that induction of nuclear
receptors does not necessarily translate to protein expression.
The functionality of P-gp in transport of Tal was investigated in P-gp induced
Caco-2 cells. The ER of Tal was significantly decreased at 50 mM EtOH after 24 h
treatment in the presence verapamil. However, the decrease in ER of Tal was not
observed in the absence of verapamil. The effect of EtOH on P-gp activity in in vivo
bioavailability of paclitaxel (P-gp substrate) was investigated previously by Fisher and
co-workers.52 They concluded that the increased bioavailability of paclitaxel in the
presence of EtOH did not arise from EtOH and/or acetaldehyde effect on P- gp;
however, EtOH- induced perturbation in TJs could be the reason. In our study, EtOH
significantly decreased the ER of Tal in the presence of P-gp inhibitor. Meanwhile, in
the absence of verapamil, the ER was insignificantly increased. According to the
transport results, it could be hypothesized that EtOH decreased the AP-BL transport of
Tal, which was resulted in increased ER. However, neither the ER, nor the AP-BL
transports of PF-57 were affected by EtOH treatment. Probably, the different drugs
binding sites on the P-gp describe this discrimination in EtOH-induced difference in
transport.

CONCLUSION
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In this study, the effect of clinically relevant EtOH concentrations on the
expression and functionality of P-gp was explored in Caco-2 cell monolayer.

IF

images showed that the abundance of P-gp decreased by increasing EtOH
concentration and treatment time.

Moreover, SWATH-MS proteomics approach

showed that the abundance of P-gp polypeptides was diminished after treatment of
normal and P- gp induced Caco-2 cells with EtOH for 4 and 24 h. Moreover, CalceinAM assay showed that by increasing the time and concentration of EtOH, the efflux
activity of P-gp was reduced in P-gp induced Caco-2 cells. Furthermore, to evaluate
the effect of EtOH on P-gp efflux functionality, ER of Tal was measured to show if
EtOH treatment at different concentrations affects the Tal efflux. According to the
results, EtOH decreased the P-gp efflux activity in the presence of verapamil.
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Table II- 1. Transport parameters of talinolol (Tal) and PF-57 conducted in normal
and P-gp induced Caco-2 monolayers
Probe
Drug

Inhibitor
(verapamil
, 200 µM)

+

Normal Caco-2
Papp (AP-BL)
(×10 -6
cm/s)

Papp (BL-AP)
(×10 -6
cm/s)

5.5 ± 3.3

16.1 ± 1.8

P-gp induced Caco-2

UR

ER

0.3 ±

2.8 ±

0.01

Tal
5.4 ± 0.3

15.1 ± 6.6

Papp (BL-AP)
(×10 -6
cm/s)

2.1 ± 0.8

6.8 ± 2.9

1.2
2.7 ±

–

Papp (AP-BL)
(×10 -6
cm/s)

0.86 ±
0.02

1.9 ±
+

27.1 ±3.6

0.5
–

12.6 ± 0.4

0.5 ± 0.1

6.6 ± 0.3

1.7 ±
3.1 ± 0.3

11.4 ± 0.4
±0.01

0.1 ±

3.2 ±

0.01

0.7

0.07 ±

13.5 ±

0.05

1.1

0.6

1.7 ±

±.04

0.1

0.1 ±

7.1 ±

0.01

0.6

22.4 ± 2.8

0.2

PF-57

ER

11.7 ± 1.1

0.3 ± 0.2
0.6

14.3 ± 1.1

UR

0.03

21.8 ± 0.5

Apical to basolateral apparent permeability (Papp (AP-BL)) and basolateral to apical
apparent permeability (Papp (BL-AP)) as well as uptake ratio (UR) and efflux ratio (ER)
across normal and P-gp induced Caco-2 cell lines are shown for Tal. Based on the
reported data, ER of Tal was increased in P-gp induced Caco-2 cells, in which P-gp is
overexpressed. All experiments were done in triplicate and data were shown as Mean
± Standard Error of Mean (Mea ± SEM, n = 3).
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Table II- 2. Expression level of efflux transporters at the apical side of normal and Pgp induced Caco-2 cells analyzed by SWATH-MS proteomics.

Proteins

EtOH
Treatments

0 (Control)
25
MDRI
50
100
0 (Control)
25
BCRP
50
100
0 (Control)
25
MRP1
50
100
0 (Control)
25
MRP2
50
100
0 (Control)
MRP3

25
50

Normalized protein
protein)
4 h treatment
P-gp
Normal
Induced
Caco-2
Caco-2
0.19
0.41
0.31
–
0.22
0.25
0.19
0.05
0.19
–
0.19
0.08
0.14
0.10
–
0.11
0.25
0.24
0.44
0.36
0.23
0.26
0.05
0.12
0.33
0.12
0.24
0.16
0.14
0.04
0.13
0.09
–
0.10
0.16
0.06
0.03
0.09
–
0.07
0.05
0.08
0.13
0.04
0.05
0.04
0.13
0.09
–
0.05
0.09
0.03
0.04
0.09
–
0.03
0.03
0.04
0.06
–
0.02
0.12
0.33
0.16
–
0.19
0.32
0.09
–
0.17
–
0.11
0.07
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abundance

(Intensity/µg

total

24 h treatment
Normal
Caco-2

P-gp Induced
Caco-2

0.17
0.22
0.14
0.11
0.20
0.16
0.12
0.10
0.26
0.35
0.32
0.22
0.38
0.26
0.25
0.14
0.05
0.08
0.10
0.05
0.12
0.06
0.10
0.05
0.05
0.05
0.04
0.03
0.06
0.03
0.06
0.04
0.18
0.23
0.15
0.15
0.17
0.09

0.21
–
0.22
0.11
0.17
0.10
–
–
0.11
0.15
0.09
0.30
0.15
–
–
0.05
–
0.12
0.04
0.10
0.07
–
–
0.10
–
0.13
–
0.06
0.03
–
–
0.20
–
0.24
–
0.15
0.15

Table II– 2. Expression level of efflux transporters at the apical side of normal and P–
gp induced Caco-2 cells analyzed by SWATH-MS proteomics.
Proteins

EtOH
Treatments
(mM)

MRP3

100
0 (Control)
25

MRP4
50
100

Normalized protein abundance (intensity/µg total protein)
4 h treatment
24 h treatment
P-gp
P-gp Induced
Normal
Normal Caco-2
Induced
Caco-2
Caco-2
Caco-2
0.11
0.17
0.10
–
–
0.08
0.07
–
0.04
0.18
0.08
0.13
0.10
–
0.05
–
0.09
0.16
0.06
0.17
0.07
0.03
–
0.03
0.09
–
0.07
0.05
0.07
0.04
0.05
0.04
0.04
0.06
0.05
–
–
0.05
0.05
–

MDR1: Multidrug resistance protein 1, BCRP: Breast cancer resistance protein,
MRP1: Multidrug resistance-associated protein 1, MRP2: Multidrug resistanceassociated protein 2, MRP3: Multidrug resistance-associated protein 3, MRP4:
Multidrug resistance-associated protein 4.
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Figure II-1
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Figure II- 1. The water-soluble tetrazolium salt (WST-1) cytotoxicity assay
WST-1 was conducted for Caco-2 cells treated with different EtOH concentrations (0–
1000 mM) for 24, 48, and 72 h. Data are shown as Mean ± Standard Error of Mean
(Mean ± SEM). No significant cytotoxicity was observed for clinically relevant EtOH
concentrations (<400 mM) for 24 h.
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Figure II- 2
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Figure II- 2. The Transepithelial Electrical Resistance (TEER) values for normal and
P-gp induced Caco-2 cells.
TEER values were compared after 4 and 24 h of EtOH treatments. The TEER value
of normal Caco-2 cells was significantly decreased after 4 h of treatment with 50 mM
EtOH compared to the control group. The TEER values of normal and P-gp induced
Caco-2 cells were significantly decreased after 24 h of treatment with the same EtOH
concentration compared to the control group. Experiments were done in triplicate and
data are shown as Mean ± Standard Error of Mean (Mean ± SEM).
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Figure II- 3

Figure II- 3. Immunofluorescent (IF) images of normal and P-gp induced Caco-2
cells treated with ethanol (EtOH) for 24 h.
Panels a) and b) show the immunofluorescent (IF) images of normal and P-gp- induced
Caco-2 monolayer in the absence of EtOH, respectively. c) Shows the normal cells
treated with 25 mM EtOH and d) illustrates the P-gp-induced cells treated with EtOH
(25 mM) for 24 h. Panels e) and f) indicate the normal and P-gp- induced cells,
respectively, 24 h after treatment with 50 mM EtOH.
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Figure II- 4

Figure II- 4. The cellular localization of P-glycoprotein (P-gp) and the quantified
peptides.
Two peptides including K.LVTMQTAGNEVELENAADESK.S (#1) and
K.GTQLSGGQK.Q (#2) are illustrated.
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Figure II- 5
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Figure II- 5. Fluorescent yield of Calcein in P-gp induced Caco-2 cells after
treatment with ethanol (EtOH).
Fluorescent yield of Calcein in P-gp induced Caco-2 cells were measured after
treatment with different EtOH concentrations (0–100 mM) for 4 and 24 h. The
concentration dependent increase in calcein fluorescent yield proved to 25 mM EtOH
and no significant increase observed in higher EtOH concentrations. Date are shown
as Mean ± Standard Error of Mean (Mean ± SEM, n = 3) and P-value <0.05
considered significant.
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Figure II- 6
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Figure II- 6. The effect of ethanol (EtOH) on the efflux ratio of talinolol (Tal) and
PF-5190457 (PF-57) in the presence and absence of P-gp inhibitor.
a) ER of Tal and b) PF-57 in the presence and absence of verapamil (200 µg/mL) after
treatment of P-gp induce Caco-2 cells with different EtOH concentrations (0–100
mM) for 24 h. Results show that ER of Tal and PF-57 was significantly (P = 0.002)
decreased in the presence of verapamil (P-gp inhibitor). Moreover, P-gp induced
Caco-2 cells treated with 50 mM EtOH showed significant decrease in ER of Tal in
the presence of P- gp inhibitor (P = 0.04) compare to the control group. Data are
shown as Mean ± Standard Error of Mean (SEM, n = 3) and P-values <0.05
considered significant.
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ABSTRACT
In this study, the effect of clinically relevant ethanol (EtOH) concentrations on the
organization of paracellular membrane proteins in Caco-2 cell monolayer was
explored. Neither EtOH, nor its metabolite, acetaldehyde (AA), showed significant
alteration in cell viability at concentrations found in GI tract. Transepithelial electrical
resistance (TEER) assay showed that the paracellular hyper permeability of Caco-2
cells induced by EtOH and AA was reversible. Fluorescent Lucifer yellow (LY)
permeation showed that paracellular transport of LY was enhanced after treatment of
Caco-2 cells with EtOH. Transmission electron microscopy (TEM) images of EtOHtreated Caco-2 cells showed the disintegration of membrane proteins including tight
junctions (TJs), adherent junctions (AJs), and desmosomes (DS).

Moreover, the

Sequential Windowed data independent Acquisition of the Total High-resolution Mass
Spectra (SWATH-MS) proteomics was used to analyze the EtOH effects on
paracellular proteins. SWATH-MS showed that the abundance of TJs, AJs, and DS
were diminished after treatment of Caco-2 cells with EtOH for 4 and 24 h.

KEYWORDS: Ethanol (EtOH), acetaldehyde (AA), Caco-2 cell monolayer, tight
junctions, adherence junction, TEER, SWATH-MS proteomics
Abbreviation:
AA: Acetaldehyde
AD: Adherense junction
CDH17: Cadherin-17
CDH23: Cadherin-23
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CTNA2: Catenin alpha-2
CTNB1: Catenin beta-1
DSC-1: Desmocollin-1
DSG 3: Desmoglein-3
DESP: Desmoplakin
DS: Desmosomes
EtOH: Ethanol
JAM: Junctional adhesion molecule A
OCLN: Occludin
SWATH-MS: Sequential Windowed data independent Acquisition of the Total
High-resolution Mass Spectra
TEER: Transepithelial electrical resistance
TJ: Tight junction proteins
ZO-3: Zonula occludens-3
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1. Introduction
Alcohol affects the gastrointestinal (GI) epithelium by altering the integrity of
epithelial cells 1 . GI tract is considered as the first line of body in contact with the
highest concentration of ingested ethanol (EtOH). Furthermore, conversion of EtOH
to its metabolite acetaldehyde (AA), which begins in upper parts of GI tract, enhances
the harmful effects of EtOH 2 . Research show that chronic EtOH exposure results in
intestinal hyper permeability (leaky gut) which has been implicated in inflammatory
bowel disorders (IBDs) 3, 4 . The role of metabolites produced by gut microbiota has
been investigated in alcohol- mediated liver diseases

5-7

. It has been evident that

existence of a gut-liver-brain axis is important in EtOH- induced organ damage

8, 9

.

Therefore, understanding the effect of alcohol on GI epithelium that plays a pivotal
role in permeation of pro- inflammatory substances is crucial to avoid further damages
in other organs.

The effect of EtOH on intestinal paracellular barriers has been

investigated in vitro and in vivo

10-12

.

However, the relative quantification of

paracellular proteins affected by EtOH exposure has not been elucidated.
The human colorectal adenocarcinoma cell line Caco-2 is widely used as a
standard model for human intestinal epithelium 13, 14 . Intestinal epithelium consists of
a single layer of epithelial cells lining the gut lumen with two main roles; First,
avoiding the passage of unwanted and harmful substances and second, the absorption
of essential nutrients. The intestinal epithelium mediates permeability through two
different routes: transepithelial and paracellular

15

.

Solute transporters at the apical

side of epithelial cells are mainly responsible for transcellular permeation.

The

paracellular pathway consists of the intercellular protein complexes between the cells.
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Figure 1a shows a schematic illustration of paracellular and transcellular pathways of
absorption. Figure 1b demonstrates the localization of uptake and efflux transporters
on apical (AP) and basolateral (BL) sides of epithelial cells. Moreover, paracellular
proteins including tight junctions (TJs), adherens junctions (AJs), and desmosomes
(DS) are depicted.
TJs form the intercellular barrier between epithelial cells that separate the tissue
space from gut lumen and regulate the solutes permeation. TJs consists of more than
40 proteins such as claudins, junctional adhesion molecule A (JAM-A) and occludin.
These transmembrane proteins are linked to the actin cytoskeleton by zonula
occludens (ZO-1, ZO-2, and ZO-3). TJs are mainly located at the apical side of lateral
membrane and are essential to form cells polarity an d mucosal barrier 16 . Like TJs,
AJs provide extracellular cell contacts through initiation and stabilization of the cellcell adhesion. AJs regulate the actin cytoskeleton and incorporate in intracellular
signaling and regulation of transcription. E-cadherin, α-catenin, and β-catenin are the
most well-known protein classes in AJs

17

. DS are intercellular junctional proteins

contributing in strong adhesion between epithelial cells. Further, DS provide high
mechanical strength in tissue because of their linkage to intermediate filament
cytoskeleton

18

.

Desmoplakin, desmogleins, and desmocollins are the most well-

known DS that have been extensively identified in epidermal and epithelial cells 19, 20 .
Enzyme- linked Immunosorbent Assay (ELISA)
immunoblotting (Western blotting)

23

21

, flow cytometry

22

, and

methods are the most well-known methods for

identification and quantification of proteins. However, those methods suffer from
some limitations such as, low throughput performance, intensive laboring, applying
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expensive antibodies, and low specificity.

In contrast to those methods, mass

spectrometry (MS) has gained a great demand in protein studies

24-26

. Among all MS-

based proteomics methods, the Sequential Windowed data independent Acquisition of
the Total High-resolution Mass Spectra (SWATH-MS) offers superior advantages,
like high accuracy and reproducibility over the other MS approaches 27 .
In the present study, the effect of EtOH on paracellular permeability of Caco-2
cell monolayer was analyzed. The cytotoxicity of EtOH and its major metabolite AA
in Caco-2 cells was examined. Transepithelial electrical resistance (TEER) assay was
used to determine the effect of EtOH and AA on opening of tight junctions.
Transmission electron microscopy (TEM) was used to visualize the EtOH effect on
paracellular proteins. The effect of EtOH and AA on paracellular transport of Lucifer
yellow (LY) was investigated. Finally, SWATH-MS proteomics approach was used to
find out if EtOH treatment can alter the expression level of TJs, AJs, and Ds in Caco-2
cells.

2. Material and methods
2.1. Chemical and Reagents
Molecular biology grade EtOH and AA >99.5%, iodoacetamide (IAA),
dithiothreitol (DTT), ammonium bicarbonate, and sodium deoxycholate were
purchased from Sigma Aldrich (St. Louis, MO). RPMI 1640, Dulbecco’s modified
Eagle medium (DMEM), fetal bovine serum (FBS), and Pierce™ BCA protein assay
kit were obtained from Thermo Fisher Scientific Inc (Waltham, MA, USA).
ProteoExtract™ Native Membrane Protein Extraction Kit was obtained from EMD
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Millipore (Billerica, MA).

WST-1 (2-(4-iodophenyl)-3-(4-nitrophenyl)-5-(2,4-

disulfophenyl)-2H-tetrazolium, monosodium salt) was purchased from Roche
(Mannheim,

Germany).

Hank's

balanced

salt

solution

(HBSS),

penicillin/streptomycin, and trypsin-EDTA (0.25%) were acquired from the American
Type Culture Collection (ATCC, VA, USA).

Optima™ LC-MS/MS grade of

acetonitrile, methanol, and formic acid were purchased from Fisher Scientific (Fair
Lawn, NJ, USA). Deionized water was obtained using a Milli-Q® Synthesis A10
system fitted with a Q-Gard 2 Purification Pack (Millipore, Bedford, MA, USA).
Proteomics grade trypsin and trypsin-predigested β- galactosidase (originated from
Escherichia coli) were purchased from SCIEX (Framingham, MA). All other reagents
used in this study were of analytical grade.

2.2. Cell Culture and EtOH Treatment
Caco-2 cells (ATCC® HTB-37™ , passage number 55–65) were kept at 37 °C and
grown in 25- ml flasks in an incubator with a controlled, humidified atmosphere
consisting of 5% CO 2 and 95% air. Cells were cultured in an enriched medium
consists of RPMI-1640, DMEM, FBS and penicillin/streptomycin in a ratio of
50:35:15:1.

The culture medium was changed every second days and cells were

trypsinized by trypsin–EDTA (1%) after reaching 70–80% confluence. Caco-2 cells
were seeded onto semi-permeable PET filter inserts (Corning Costar Corporation,
Corning, NY) with 6.4 mm diameter, 0.33 cm2 growth area, and 0.4 µm pore size.
Each membrane of the 24-transwell permeable insert received 0.2 mL of a 3.2 × 105
cells/mL suspension and 0.6 mL culture medium into the wells. Caco-2 cells were
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then grown and differentiated for 21 days. Medium changed every two days for the
first two weeks and then every day until day 21 when a fully differentiated monolayer
had achieved.
The effect of EtOH and AA on paracellular membrane proteins in normal and Pgp- induced (10 nM vinblastine- induced) Caco-2 monolayer was assessed. Briefly, the
plates containing transwell inserts were put into chambers filled with 95% air, 5% CO 2
and kept in humid incubator at 37 °C. Various EtOH (25, 50, and 100 mM) and AA
(100 µM) diluted in culture medium were added to the both apical and basolateral
sides of cells. In each treatment, the atmosphere of chambers was saturated by the
same concentration of EtOH and AA.

2.3. Cytotoxicity Assay
The cytotoxicity of EtOH and AA treatment on the Caco-2 cells was evaluated
according to the colorimetric method using a water-soluble tetrazolium salt (WST-1).
In this method, the cleavage of the tetrazolium salt to formazan by active cellular
mitochondrial dehydrogenases indicates the viable cells. For this purpose, Caco-2
cells were seeded at a concentration of 2 × 104 cells/well in a 96-well plate for 2–3
days to achieve 70% confluence. The culture medium was removed and replaced by
different EtOH (0–1000 mM) and AA (0–1000 µM) concentrations and placed in the
corresponding chambers saturated with EtOH and AA vapor contained 95% air and
5% CO2 and placed in incubator.

Clotrimazol was used as a positive control at

different concentrations (20, 40, 60, 80, and 100 µM). Cells were incubated for 24,
48, and 72 h at 37 °C in an incubator with a controlled atmosphere. At the end of
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treatment, 10 µl of WST-1 was added to each well and incubated for 4 h at 37 °C. The
absorbance of each well against background control was measured at 450 nm, while
reference wavelength set at 650 nm.

2.4. Transepithelial Electrical Resistance (TEER)
TEER is widely used as a real-time, non-destructive, and label free method to
characterize the quality of the epithelial or endothelial barrier function in cell
monolayer.

TEER assay was used as a real-time, non-destructive, and label free

method to characterize the quality of the cell monolayer integrity. The TEER of the
normal and P-gp- induced Caco-2 cell monolayers were evaluated by an EVOM2
(World Precision Instruments, Sarasota, FL) equipped with STX2 “chopstick”
silver/silver chloride (Ag/AgCl) electrodes.

TEER comprises from four different

resistance on cell membrane that has been mentioned in Eq. 1.
TEER =

( Ra + Rb).( Rtj + Ric)
( Ra + Rb) + ( Rtj + Ric)

(1)

Where, Ra stands for apical cell membrane resistance, Rb is basolateral cell
membrane resistance, Rtj represent for tight junction resistance, and Ric expresses the
intercellular resistance 28 .
TEER assay was performed 21-days post seeding of normal and vinblastinetreated Caco-2 cells on filter inserts. TEER measurements were done before starting
of EtOH treatment as well as 4 and 24 h after alcohol exposure to the Caco-2
monolayers. The relative changes in TEER values before and after EtOH treatments
were compared to that for buffer treatment, as the control group. TEER values were
calculated according to the following equation (Eq.2):
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TEER = (Rmonolayer ‒ Rblank ) × A (Ωcm2 ),

(2)

where, Rmonolayer is the measured resistance of cell monolayer, Rblank represents the
resistance of filter inserts without cell monolayer, and A is the available filter inserts
surface area.

2.5. Transmission electron microscopy (TEM)
Caco-2 cell monolayers, grown on Transwell filter membranes, were fixed with
1.5% glutaraldehyde in 0.15 M sodium cacodylate buffer at 4 °C for several days.
Fixative, as with all reagents listed below, was always applied to both the apical and
basolateral chambers of the Transwell filter units.

Following fixation, cells were

rinsed in buffer and post- fixed in 1% osmium tetroxide for 1 hour at 4 °C. Cultures
were buffer rinsed and dehydrated through a graded ethanol series.

Ten minute

changes were used for each ethanol step, 35, 50, 70, 80, 90, and 95% ethanol, all at 4
°C. Six changes, 10 min each, of absolute ethanol at room temperature served to
completely dehydrate the sample.

Infiltration was initiated by introducing a 1:1

mixture of ethanol and Epox 812 resin to the chambers. One 10 minute change of
pure Epox 812 resin was followed by a fresh change and held for 1.5 hours at 37 °C.
Finally, Transwell inserts were placed in the cut-off bulb end of a disposable transfer
pipette, filled with fresh resin, and polymerized for 20 hours at 60 °C. A small
rectangle of resin surrounding the filter membrane was cut out using a jeweler’s saw,
and trimmed for cross-sectioning of the filter membrane. Semi- thin sections (1µm)
were prepared using a Reichert Ultracut S microtome (Leica Biosystems, Buffalo
Grove, IL) stained with methylene blue-azure II and evaluated for areas of interest.
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Ultra-thin sections (60 nm) were prepared and retrieved onto 200 mesh copper grids
with formvar/carbon coating. Sections were contrasted with uranyl acetate and lead
citrate stains. Sections were examined at 80 kV using a CM-10 electron microscope
(FEI, Hillsboro, OR). Images were collected with a model 785 Erlangshen ES1000W
CCD camera, using Digital Micrograph imaging software (version 1.71.38) (Gatan,
Pleasanton, CA).

2.6. LY Permeation through Caco-2 monolayer
Permeation of LY, a fluorescent marker, used to verify tight junction integrity in
Caco-2 monolayers. Caco-2 cells were seeded onto semi-permeable PET filter inserts
(Corning Costar Corporation, Corning, NY) with 6.4 mm diameter, 0.33 cm2 growth
area, and 0.4 µm pore size. Prior to monitoring flux through the paracellular pathway,
mature Caco-2 cell monolayers (21-day seeded on filter insert) and non- mature (10day seeded on filter insert) were washed twice with pre-warmed HBSS medium (pH
7.4).

After washing, the permeation experiments were done by adding LY (0.5

mg/mL) to the apical side (AP, 200 µL) and basolateral side (BL, 600 µL) of the cell
monolayer while the receiving chamber contained the corresponding volume of
transport medium (HBSS-HPES).

After shaking at 55 rpm for 4 h at 37 °C in

incubator, samples were collected from both sides of Caco-2 cell monolayer.
Aliquots (100 μL) of AP and BL were transferred to a CELLSTAR black, clearbottom 96-well plate (Grenier, #M0562) and measured on a Molecular Device
SpectraMax® M 5 plate reader. The fluorescence of LY in each compartment was
measured at an excitation of 435 nm and an emission of 540 nm.
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Apparent permeability coefficient (Papp ) of LY was calculated according to the
following equation:

Papp =

dM r
1
,
×
dt
A × C D (0)

(3)

where, A stands for surface area of the cell monolayer (0.33 cm2 ), CD (0) is the
initial concentration of the drug added to the donor compartment, t is the time of
transport, Mr represents the mass of compound in the receiver side, and dMr /dt
accounts for the flux of the drug across the cell monolayer. Uptake ratio (UR) and
efflux ratio (ER) were obtained as below;
𝑃𝑃

(4)

𝑃𝑃

(5)

UR = 𝑃𝑃app (AP-BL)
app (BL-AP)

ER = 𝑃𝑃app (BL-AP)
app (AP-BL)

where, Papp (AP-BL) and Papp (BL-AP) stand for apparent permeability from AP to BL

and BL to AP sides, respectively.

2.7. Membrane Protein Extraction and Sample Preparation
The expression level of junctional membrane proteins were analyzed in normal
Caco-2 cells (PN = 55–65) as well as vinblastine- induced Caco-2 cells (PN = 55–65).
Vinblastine- induced Caco-2 cell line was obtained by treatment of normal Caco-2
cells were with 10 nM vinblastine for 4–5 passages

29, 30

. Membrane associated

proteins were extracted from normal and vinblastine- induced Caco-2 cells using the
ProteoExtract™ Native Membrane Protein Extraction Kit (M-PEK, EMD Millipore,
Billerica, MA).

For this purpose, normal and vinblastine- induced Caco-2 cells

(passage number 55–65) were seeded at the density of 6.5 × 104 cells per each 24-well
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PET filter inserts for 15–21 days. By the end of time needed for cell differentiation,
cells were treated with EtOH (25, 50, and 100 mM) and placed in saturated chambers
filled with 95% air, 5% CO 2 for 4 and 24 h and kept in humid incubator at 37 °C. To
obtain membrane associated proteins from filter-grown Caco-2 cells, the attached cells
were scratched by cell scraper from the filter inserts. Then, the cells were incubated in
100 µl of extraction buffer I containing 0.5 µl of protease inhibitor cocktail according
to the protocol supplied by the vendor. The cell suspension was gently shaken for 10
min at 4 °C and the homogenate was centrifuged at 3000 × g for 5 min to separate
soluble proteins from cell pellet.

To extract the membrane proteins, 100 µl of

extraction buffer II containing 0.5 µl of protease inhibitor cocktail was added to the
cells and shacked at 4 °C for 30 min.

Finally, the enriched homogenate with

membrane bounded proteins was collected from supernatant.
To digest proteins, 100 µL of 1 mg/mL of soluble and membrane bounded
proteins were incubated with 15 µL of dithiothreitol (100 mM) and 50 ml of
ammonium bicarbonate buffer (50 mM, pH 7.4) at 95 °C for 10 min. Afterward, 15
µL of iodoacetamide (150 mM) was added to the mixture and incubated at room
temperature for 30 min in the dark. Ice-cold chloroform extraction solution (0.5 mL)
which contains (MeOH 50%, CHCl3 25%, and water 25%) was added to each sample
and centrifuged at 4 °C for 5 min at 16000 × g. The protein pellet was washed with
ice-cold methanol (250 µL) and resuspended in 46.5 µL of sodium deoxycholate (3%
w/v) solution prepared in ammonium bicarbonate buffer (50 mM, pH 7.4). Then, 3.5
µL of trypsin (1 mg/mL) was added to the latter solution and put in the Barocycler®
2320 EXT (Pressure Biosciences; West Bridgewater, MA) to digest the proteins.
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Protein to trypsin ratio was 20:1 (w/w). Barocycler repeated cycles of hydrostatic
pressure at 35000 psi for 90 cycles (90 min) to improve the protein digestion.
Afterwards, 10 µL of 2.5% formic Acid in 1:1 (v/v) mixture of water/acetonitrile was
added to the digest and centrifuged at 10,000 ×g for 5 minutes at 4°C. Finally, 2.5 µL
of β- galactosidase (31.25 pmol), as an external control, was added to the digested
protein solution before injection to LC-MS/MS.

2.8. SWATH-MS Analysis
The SWATH-MS proteomics analysis and data processing were accomplished
based on the previously published method

31, 32

. Briefly, A SCIEX 5600 TripleTOF

mass spectrometer equipped with a DuoSpray ion source (SCIEX, Concord, Canada)
coupled to Acquity UHPLC HClass system (Waters Corp., Milford, MA, USA) was
used. The mass spectrometer was operated in positive electrospray ionization (ESI)
mode for all the experiments. Compound and source/gas parameters used in SWATHMS method were as follows: DP = 120 V, CE = 10 V, collision energy spread (CES =
5V), TEM = 400 °C, ISVF = 5500 V, GS1 = 55 psi, and GS2 = 60 psi. TOF masses
were collected from m/z 300 to 1500. SWATH data was acquired in the range of m/z
400 to 1100 over 70 SWATH windows per cycles with a window size of m/z 10. The
total cycle time for SWATH acquisition was 3.95 sec.
The digested P-gp peptides were separated on an Acquity UHPLC Peptide BEH
C18 (2.1 × 150 mm2 , 300 Å, 1.7 μm) equipped with Acquity VanGuard precolumn
(2.1 × 5 mm2 , 300 Å, 1.7 μm). Autosampler temperature was kept at 10 °C and the
column temperature was maintained at 40 °C during all injections.
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The

chromatographic separation was performed with a runtime of 120 min at 100 μL/min
with a gradient method using mobile phase A (98% water, 2% acetonitrile, 0.1%
formic acid) and mobile phase B (98% acetonitrile, 2% water, 0.1% formic acid). A
gradient chromatographic elusion method was performed as follows: 98% A from 0 to
3 min, 60% to 90% A from 3 to 48 min, 20% A held from 49 to 52 min to flush the
column, 98% A at 53 min. The column was allowed to equilibrate at 98% A from 53
to 60 min before the start of next run. The amount of protein per injection on the
column was 10 μg. In each batch, trypsin-digested β- galactosidase that is a quality
control standard (1.65 pmol/injection) was injected to each sample to monitor mass
calibration of the TOF detector and normalization of peptides intensity in SWATH
label free quantification (LFQ) approach. The LFQ was performed using Skyline,
which is an open source application for targeted proteomics quantitative data analysis.

2.9. Protein Quantification
Membrane Proteins and digested peptides concentrations were analyzed using
Pierce™ BCA protein assay kit (Thermo Fisher Scientific, Rockford, IL, USA) and
NanoDrop™ 2000 (Thermo Fisher Scientific, Wilmington, USA) by measuring UVvis absorbance at wavelengths of 562 and 280 nm, respectively. Protease-free bovine
serum albumin (BSA) solutions (125–2000 µg/mL) were used as the standard
calibration line for the BCA protein quantification method.

2.10. Statistical Analysis
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Results are reported as Mean ± Standard Error of Mean (SEM) from three
independent experiments unless otherwise mentioned. The normality of data sets in
each experiment was checked with Shapiro-Wilk test. Non-parametric Mann-Whitney
U test was used in the case of non-normal distributions. One-way analysis of variance
(ANOVA) with Dunnett's T3 post hoc test (SPSS 23, SPSS, Inc.) was used for
normally distributed observations.

In all analyses, probability values <0.05 was

considered significant.

3. Results and discussion
3.1. WST-1 cytotoxicity
Figure 2 shows the cytotoxicity profiles of EtOH, AA, and clotrimazole on Caco2 cell line examined by WST-1 assay. Figure 2a illustrates the viability percentage of
Caco-2 cells after 24, 48, and 72 h treatment with EtOH. According to the graph, the
EtOH and buffer exposure experiments showed that alcohol cytotoxicity was
increased in a time- and EtOH concentration-dependent manner (Figure 2a). The
viability% of Caco-2 cells was reduced by increasing EtOH treatment time from 24 to
72 h. Moreover, by increasing EtOH concentration from 0 to 1000 mM, the cell
viability was decreased, accordingly. Figure 2a shows that after 72 h of treatment, the
viability of Caco-2 cells was decreased to 85, 78, and 47% at EtOH concentrations of
250, 500, and 1000 mM, respectively. In the case of buffer treatment, cell viability
was 85% in 1000 mM buffer-treated group after 72 h treatment (Figure. 2a). Figure
2b shows the cytotoxicity profile of AA (0–1000 µM). No significant cytotoxicity
was seen at clinically relevant AA concentrations (100 µM) after 72 h treatment.
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Figure 2c shows the viability of Caco-2 cells after treatment with clotrimazole (0-100
µM) for 24, 48, and 72 h. According to the graph, the Caco-2 viability reduced to 80.4
± 9.0, 75.4 ± 2.3, and 17.9 ± 3.4 % after 24, 48, and 72 h of treatment, respectively.
Cytotoxicity results showed that at EtOH concentration < 500 mM, which is more
clinically relevant, no significant cytotoxicity is induced by EtOH compared to the
control group (buffer-treated cells). Further, AA did not show significantly reduction
in cell viability even after three days of incubation at 1000 µM. Elamin and coworkers have previously shown that exposure of Caco-2 spheroids to EtOH and AA
did not show any significant reduction in cell viability 33 .

3.2. TEM images
Figure 3 shows the effect of EtOH treatment on the organization of microvilli and
paracellular barrier in Caco-2 cells. TJs are mentioned in TEM images at the apical
side of lateral membrane with 1–2 nm thickness (Figure 3a and c). Figure 3a and c
show the organization of TJs, AJ, and DS between two buffer-treated Caco-2 cells.
According to the Figure 3a and c, the paracellular barriers between two cells are
tightly formed and there is no space between cells. Figure 3b shows the effect of 50
mM EtOH treatment on junctional barrier between cells. According to the picture, the
organization of junctional proteins is disrupted after 24 h incubation of cells with 50
mM EtOH. Figure 3d shows the deformation of microvilli at the top of cells in the
presence of EtOH (100 mM). In addition, the organization of TJs, AJs, and DS were
disrupted after 24 h treatment of cells with 100 mM EtOH. Elamin and co-workers
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had shown the same effects of EtOH on the integrity of paracellular barrier in Caco-2
spheroids 34 .

3.3. EtOH and AA effects on TEER
Figure 4a shows the TEER assay of normal Caco-2 cells treated with different
EtOH concentrations (25, 50, and 100 mM) during 4 h and one day after removal of
EtOH. Data shows a slight decrease in TEER values by the time. At the end of 4 h
treatment, the medium contained EtOH was removed and cells were cultured in
normal medium. One day after EtOH removal, the TEER was checked and it showed
that paracellular barrier was revitalized after EtOH removal. The transient disruptive
effect of single dose EtOH on intestinal permeability was previously observed by
Robinson et al

35

. However, persistent changes may occur after prolonged chronic

alcohol consumption 36 .
Figure 4b shows the TEER changes of Caco-2 cells after 24, 48, and 72 h of
treatment with buffer and EtOH (50 mM) and after removal. Results show that there
is no significantly change in TEER values during buffer-treatment and one day after
removal. (Figure 4b). After 24 h of treatment with 50 mM EtOH, a statistically
significant decrease (P = 0.002) was observed in TEER values. The TEER values of
Caco-2 cells did not significantly change during 48 and 72 h. Figure 4b shows that
the TEER value of EtOH-treated Caco-2 cells increased to near 600 Ωcm2 that was
comparable to the buffer-treated cells (P = 0.13). This means the effect of EtOH on
the integrity of paracellular barriers are transient and it could be revitalized after
alcohol removal.
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The reduction in TEER value by EtOH in Caco-2 cells was reported previously.34,
37, 38

Fisher and co-workers suggested that EtOH and its metabolite acetaldehyde are

able to increase the paracellular permeability of Caco-2 cells without altering
viability.34 The proposed mechanism for EtOH-induced enhancement in paracellular
permeability is disruption of TJs proteins. The proposed mechanism is activation of
myosin light chain kinas (MLCK) which results in phosphorylation of MLC and
occluding and subsequently destabilization of TJs 39, 40 .

3.4. Lucifer yellow permeability assay
Table 1 shows the permeability of LY, a fluorescent marker for paracellular
pathway, across mature (highly integrate paracellular barrier) and non- mature (loose
barrier) Caco-2 monolayers. As shown in the Table 1, the apical (AP) to basolateral
(BL) permeability (Papp

(AP-BL) )

of LY drastically decreased in mature Caco-2

monolayer compared to the non- mature cells. This result confirmed the formation of
tight junction proteins in mature Caco-2 cell monolayer after 21-days of seeding on
filter insert.
The effect of EtOH and its metabolite, acetaldehyde (AA), on the integrity of tight
junctions is shown in Fig 5. Results show that EtOH (100 mM) and AA (100 µM)
increased the Apical to basolateral (Papp (AP-BL)) apparent permeability of LY (500 µM)
across Caco-2 monolayer. The increased LY permeation was statistically significant
in the presence of EtOH (100 mM), while it was not increased significantly in the
presence of AA. This suggests that in accordance to the other published literature
37

, EtOH and AA are responsible for tight junction opening.
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34,

3.5. SWATH-MS proteomics
Table 2 shows the abundance of TJs, AJs, and DS after 24 h treatment with 25,
50, and 100 mM EtOH versus control group. According to the results, the relative
expression of JAM-A was decreased after 4 and 24 h treatment of vinblastine- induced
cells with 50 mM EtOH (Table 2). Chopyk and co-worker have shown that EtOH
decreases JAM-A protein expression level to ~ 70% of control in a concentration-and
time-dependent manner in Caco-2 monolayer 41 .
Cresci et al have shown that EtOH-exposed mice showed reduction in the
expression and co- localization of zonula occludens-1 (ZO-1) and occludin in the ileum
and proximal colon

42

. The reduction in occludin and ZO-3 expression level was

confirmed in our study using normal and vinblastine- induced Caco-2 cells (Table 2).
Moreover, Zhao and co-workers have shown that EtOH exposure in mice decreased
the expression of occludin leading to intestinal hyper permeability 43 . They revealed
that chronic consumption of EtOH results in depletion of occluding expression in mice
intestine followed by increase in paracellular permeability. In a previous attempt, Ye
et al has found that increase in microRNA122a (miR122a), enhanced by tumor
necrosis factor-α (TNF-α), is responsible for occludin degradation and subsequent
enhancement in paracellular permeation

44

. It could be concluded that the intestinal

hyper permeability induced by chronic EtOH is mediated by increased TNF-α 45 and
miR122a expression and consecutively occludin down regulation.
The expression of CAD17 and CAD23 showed insignificant decrease in
expression level after 4 h treatment of normal and vinblastine- induced Caco-2 cells
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with 50 mM EtOH (Table 2). However, normal and vinblastine-induced Caco-2 cells
treatment with 50 mM did not show any decrease in expression level.
It has been mentioned that the levels of gut AJs (e.g., β-catenin and E-cadherin)
and desmosome plakoglobin were clearly decreased in binge alcohol-exposed rats 46 .

Conclusion
In this work, the effect of EtOH on paracellular integrity was examined in Caco-2
cell monolayer. WST-1 mitochondrial cytotoxicity assay was carried out on Caco-2
cells after EtOH and AA treatment. EtOH and AA did not show significant alteration
in cell viability at concentrations found in GI tract. Moreover, TEER assay showed
that the paracellular hyper permeability of Caco-2 cells induced by EtOH and AA was
reversible after removal of reagents.

LY permeation showed that paracellular

transport of LY was enhanced after treatment of Caco-2 cells with EtOH.

TEM

images of EtOH-treated Caco-2 cells showed the disintegration of TJs, AJs, and DS.
Moreover, SWATH-MS proteomics was used to analyze the effect of 50 mM EtOH on
paracellular proteins in normal and vinblastine- induced Caco-2 cells for 4 and 24 h.
Proteomics data showed that the abundance of TJs, AJs, and DS were diminished after
treatment of Caco-2 cells with EtOH (50 mM) for 4 and 24 h. However, the reduction
of junctional proteins was not statistically significant in any of the treatments. This
fact confirmed that other molecular pathways are involved in paracellular opening by
EtOH.
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Table III- 1. Permeability of Lucifer yellow (LY) across mature and non- mature
Caco-2 cells monolayers.
Caco-2 monolayer Papp (AP-BL) (× Papp (BL-AP) (×
UR
ER
10-6 cm/s)
10-6 cm/s)
Non-mature
21.55 ± 1.42 20.67 ± 1.17
1.04 ± 0.01
0.96 ± 0.01
Mature

0.18 ± 0.06

0.34 ± 0.07

0.53 ± 0.17

1.99 ± 0.56

Apical to basolateral (Papp (AP-BL)) and basolateral to apical apparent permeability (Papp
(BL-AP) ) as well as uptake ratio (UR) and efflux ratio (ER) across mature and nonmature Caco-2 cells monolayers. Data are shown as Mean ± SEM (n = 3).
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Table III- 2. Relative expression level of tight junction (TJ), Adherens junction (AJ),
and desmosome (DS) proteins in EtOH-treated normal and Pgp- induced Caco-2 cells.

Proteins

Protein
class

EtOH
Treatments

0 (Control)
Junctional
adhesion
molecule
A

25
50
100
TJ
0 (Control)
25

ZO-3
50
100
0 (Control)
25

Cadherin17

50
100
AJ
0 (Control)

Cadherin23

25
50
100

Normalized protein abundance (Intensity/µg
total protein)
4 h treatment
24 h treatment
P-gp
Normal P-gp Induced Normal
Induced
Caco-2
Caco-2
Caco-2
Caco-2
0.48
0.80
0.57
0.58
0.61
–
0.52
–
0.66
0.91
0.62
0.87
0.39
0.22
0.34
0.28
0.60
–
0.68
0.55
0.48
0.30
0.41
0.38
0.48
0.68
0.50
–
–
0.36
0.32
–
0.02
0.07
0.04
0.06
0.02
–
0.04
–
0.03
0.07
0.03
0.08
0.04
0.10
0.03
0.08
0.04
–
0.04
0.02
0.04
0.02
0.03
0.03
0.02
0.03
0.02
–
–
0.03
0.01
–
0.10
0.11
0.10
0.05
0.03
–
0.02
–
0.12
0.10
0.12
0.08
0.02
0.01
0.01
0.01
0.07
–
0.12
0.12
0.02
0.01
0.02
0.01
0.09
0.08
0.08
–
–
0.02
0.02
–
0.12
0.09
0.10
0.03
0.12
–
0.05
–
0.17
0.06
0.12
0.04
0.06
0.04
0.05
0.04
0.05
–
0.16
0.14
0.07
0.03
0.06
0.03
0.09
0.03
0.10
–
–
0.04
0.05
–
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Table III– 2. Relative expression level of tight junction (TJ), Adherens junction (AJ),
and desmosome (DS) proteins in EtOH-treated normal and P-gp- induced Caco-2 cells.

Proteins

Protein
class

EtOH
Treatme
nts
0
(Control)
25

Catenin alpha2

50
100
AJ

0
(Control)
25

Catenin beta-1
50
100
0
(Control)
25
Desmoplakin
50
100
DS

0
(Control)
25

Desmoglein-3
50
100

Normalized protein abundance (Intensity/µg
total protein)
4 h treatment
24 h treatment
Norma
P-gp
P-gp Induced
Normal
l CacoInduced
Caco-2
Caco-2
2
Caco-2
0.05
0.08
0.09
0.03
0.07
–
0.06
–
0.08
0.07
0.04
0.05
0.03
0.02
0.04
0.03
0.04
–
0.06
0.06
0.03
0.01
0.03
0.03
0.05
0.04
0.05
–
–
0.02
0.02
–
0.07
0.09
0.07
0.04
0.08
–
0.08
–
0.11
0.08
0.09
0.04
0.05
0.02
0.05
0.02
0.04
–
0.10
0.09
0.06
0.03
0.05
0.03
0.08
0.06
0.07
–
–
0.04
0.04
–
0.26
0.80
0.28
0.47
0.22
–
0.11
–
0.40
0.58
0.39
0.61
0.07
0.11
0.06
0.03
0.48
–
0.42
0.27
0.08
0.10
0.09
0.05
0.18
0.19
0.16
–
–
0.08
0.06
–
0.17
0.78
0.25
0.39
0.25
–
0.27
–
0.21
0.42
0.14
0.37
0.08
0.25
0.21
0.05
0.35
–
0.21
0.14
0.09
0.12
0.11
0.10
0.14
0.11
0.10
–
–
0.10
0.15
–
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Figure III– 1

a)

b)

Figure III- 1. Schematic illustration of human epithelial cells demonstrating the
involved proteins in paracellular and transcellular routes.
a) Two main routes of drug transport across epithelial cell monolayer are paracellular
and transcellular pathways. Transcellular pathway (Rtrc) is the sum of Ra and Rb
(apical and basolateral resistance). The paracellular pathway (Rpc) equals to tight
junction resistance (Rtj) plus intercellular resistance (Ric). Rgap indicates the partial
cell coverage of the cell support. b) A schematic illustration of human epithelial cells.
The uptake and efflux transporters on apical (AP) and basolateral (BL) sides of cells
are indicated. Moreover, paracellular proteins including tight junctions (TJs),
desmosomes (DS), and adherens junctions (ADs) are depicted.
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Figure III- 2
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Figure III- 2. The water-soluble tetrazolium salt (WST-1) cytotoxicity assay
conducted for Caco-2 cells treated with ethanol (EtOH), acetaldehyde (AA), and
clotrimazole (CTZ).
WST-1 cytotoxicity profile for a) EtOH (0–1000 mM), b) AA (0–1000 µM), and c)
CTZ (0–100 µM) for 24, 48, and 72 h are illustrated. No significant cytotoxicity was
observed at clinically relevant EtOH and AA concentrations (<400 mM and 100 µM,
respectively) after 72 h treatment. However, viability (%) for Caco-2 cells treatment
with 60 µM CTZ (positive control) was 20% after 3 days treatment. Data are shown
as Mean ± Standard Error of Mean (Mean ± SEM, n=3).
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Figure III- 3

Figure III- 3. Transmission electron microscopy (TEM) images of buffer- and EtOHtreated Caco-2 cells for 24 h.
Panels a and c) show the TEM images of buffer-treated (50 and 100 mM) Caco-2 cells
after 24 h. b and d) illustrate the images of EtOH-treated (50 and 100 mM) Caco-2
cells for 24 h. Deformation of MV at the top of cells was observed in after treatment
with 100 mM EtOH (Figure 3d). However, Caco-2 treatment with 50 mM EtOH
(Figure 3b) did not affect the MV and the structure of MV after 24 h treatment with
50 mM EtOH was comparable to the control groups (Figure 3a and c). The
organization of tight junctions (TJs), adherens junctions (ADs), and desmosomes (DS)
are disrupted after 24 h treatment of cells with 50 and 100 mM EtOH (Figure 3b and
d) compare to the control groups (Figure 3a and c).
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Figure III- 4
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Figure III- 4 Transepithelial electrical resistance (TEER) assay of normal Caco-2
cells treated with different EtOH concentrations and treatment time.
a) TEER assay of normal Caco-2 cells treated with different EtOH concentrations (25,
50, and 100 mM) during 4 h and one day after removal of EtOH. Data shows a slight
decrease in TEER values during the time and while it revitalized after EtOH removal.
b) TEER assay of normal Caco-2 cells treated with 50 mM EtOH during 24, 48, and
72 h and one day after removal of EtOH. Data show that there is no significant
difference in TEER values one day after removal of EtOH and buffer. Date are shown
as Mean ± Standard Error of Mean (Mean ± SEM, n = 3) and P-value <0.05
considered significant.
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Figure III-5
20
EtOH (100 mM)
AA (100 µM)
Buffer (control)

-6

Papp (× 10 cm/s)

15

10

P = 0.72
P = 0.1

5

0

l
t
t
va
en
en
o
m
m
t
ri
re m
re a
pe
r
t
x
e
e
h
aft
re
24
y
o
f
a
r
te
be
ed
n
Af
O
Figure III- 5. The effect of ethanol (EtOH), acetaldehyde (AA), and buffer (control)
on the permeation of Lucifer yellow (LY) across Caco-2 cell monolayer.
Caco-2 cells treatment with EtOH (100 mM) and AA (100 µM) for 24 h increased the
LY permeation compare to buffer as control. No significant difference was observed
one day after reagents removal compared to the control. Date are shown as Mean ±
Standard Error of Mean (Mean ± SEM, n = 3) and P- value <0.05 considered
significant.
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Abstract
In this study, SWATH-MS proteomics was successfully used for quantitative
analysis of proteins obtained from limited biopsy samples. Accordingly, the proteome
of healthy human sigmoid was compared to alcoholic subjects with and without liver
disease. Moreover, proteome of different parts of gastrointestinal (GI) tract from
chronic-binge rat models was compared to control group. Results showed that the
expression level of aldehyde dehydrogenase2 (ALDH2) in alcoholic human subjects
without liver disease “low quartile sucralose” (AWLDLQ) was significantly (P = 0.02)
higher than that in healthy control (HC). Interestingly, the expression of ALDH2 in
AWLDLQ was higher than that in AWLDHQ. Moreover, filamin A expression in
AWLDLQ human subjects was significantly lower than that in HC. Glutathione Stransferase A1 (GSTA1) expression in AWLDLQ was higher than that in HC. Higher
expression of GSTA1 in AWLDLQ may explain the insignificant antioxidant role of
GSTA in human colon compared to liver. Furthermore, the expression of vimentin
(Vim), a cytoskeletal protein, was increased in proximal colon (pCol) of chronic-binge
rat models.

Thus, SWATH-MS proteomics was capable to analyze very limited

quantity of biopsy tissue.

This technique might be helpful in identification of

alcoholism biomarkers and developing new drugs to cure different stages of
alcoholism.

Keywords: SWATH-MS Proteomics, Sigmoid colon, Chronic-binge rat model
Abbreviations:
ALD: Alcoholic Liver Disease
ALDH2: Aldehyde dehydrogenase2
AWLDLQ: Alcoholic without Liver Disease Low Quartile Sucralose
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AWLDHQ: Alcoholic without Liver Disease High Quartile Sucralose
dCol: Distal Colon
GSTA1: Glutathione S-transferase A1
HC: Healthy Control
pCol: Proximal Colon
PCT-Micropestle: Pressure-cycling technology- MicroPestle
SWATH-MS: Sequential Windowed data independent Acquisition of the Total
High-resolution Mass Spectra
Vim: Vimentin
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1. Introduction
Alcohol abuse or alcohol use disorder (AUD) is considered as an untreated
epidemic health concern in modern societies 1 . According to the 2014 report of World
Health Organization (WHO), alcoholism causes approximately 6% of all cases of
death every year.2, 3 While, moderate alcohol drinking (≤1 drink/day for women and
≤2 drink/day for men) does not show clinical problems and even is beneficial for
health4 , heavy chronic drinking (binge drinking) increases the risk of organ damage.5
Alcohol affects the gastrointestinal (GI) epithelium by altering the intestinal
epithelial function.

Chronic ethanol (EtOH) exposure results in intestinal hyper

permeability (leaky gut) which has been implicated in inflammatory bowel disorders
(IBDs). Moreover, chronic alcohol consumption leads to liver damage6 . Studies show
that the risk of cirrhosis is enhanced by increasing the amount of drinking alcohol.
Alcoholic liver disease (ALD) comprises a wide spectrum of liver disorders ranging
from alcoholic steatosis to alcoholic steatohepatitis (ASH), alcoholic hepatitis,
progressive fibrosis, cirrhosis, and hepatocellular carcinoma.5,

7

Reports show that

while a majority portion of heavy alcohol drinkers develop steatosis, only a minority
of patients with steatosis progresses to ASH and subsequently cirrhosis and carcinoma
8, 9

. There is evidence suggesting that EtOH is not the only reason in progression of

liver diseases but also the existence of a gut- liver-brain axis needs to be considered as
another player. Consequently, many pathophysiological mechanisms that are affected
by EtOH exposure and implicated in disease development remained unknown. Hence,
analyzing proteome of alcoholic patients would be beneficial to explore protein
biomarkers for early detection and treatment of alcohol-related diseases in liver and GI
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tract 5 . It has been evident that the paracellular permeability in GI tract could be
considered as a practical indicator to determine the severity of EtOH damage.
The artificial sweetener sucralose (a chlorinated derivative of sucrose) is
considered as a useful GI tract permeability probe10 .

Resistance of sucralose to

bacterial fermentation makes it as a suitable marker for whole GI tract permeability.
The higher urinary excretion of sucralose indicates the higher gut leakiness.11 The
usefulness of sucralose permeation in determining gut leakiness has been investigated
in alcoholic steatohepatitis.12 The alcoholic subjects without liver disease can be
categorized into low quartile and high quartile sucralose permeation groups. This
categorization might be helpful to show the level of damage induced by EtOH in GI
tract.
Various proteomics approaches have been used to determine the effect of EtOH at
the cellular level.

Mass spectrometry (MS) with LC-MS/MS has gained a great

demand in proteomics and protein studies.13-15

Among all MS approaches, the

Sequential Windowed data independent Acquisition of the Total High-resolution Mass
Spectra (SWATH-MS) offers superior advantages, like high accuracy and
reproducibility over the other MS methods.

SWATH-MS is a data-independent

acquisition (DIA) method that acquires all MS/MS fragments by recording all
theoretical fragment spectra produced from the precursor ions.
In this study, the proteome of sigmoid colon obtained from healthy human
subjects was compared with that in ALD patients. Furthermore, alcoholic patients
with no liver disease and different intestinal permeability were also examined.
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Moreover, the proteome of GI tract of chronic-binge rat model was investigated and
compared with that in control rats.

2. Experime ntal Section
2.1. Human intestinal Tissue
Human sigmoid colon samples were generously provided by Dr. A. Keshavarzian
from Rush University Medical Center (RUMC, Chicago, IL).

Briefly, mucosal

biopsies from healthy control (HC), alcoholic liver disease (ALD), alcoholic without
liver disease low quartile sucralose permeation (AWLDLQ), and alcoholic without
liver disease high quartile sucralose permeation (AWLDHQ) volunteers were
obtained. These samples were collected via endoscopy at the RUMC Endoscopy Lab
obtained from six HC (three females, three males; 25−63 years old), six ALD (five
female, one male; 48−63 years old), six AWLDLQ (three female, three male; 43−56
years old), and six AWLDHQ (two female, four males; 40−68 years old). The urinary
concentration of excreted sucralose was used to categorize the groups of alcoholic
patients without liver disease into low and high quartile sucralose.11, 16 Samples were
snap frozen in liquid nitrogen in the endoscopy room. Then, sigmoid biopsies were
stored at -80°C until the time of tissue lysis for proteomics analysis. The details of
procedure method and inclusion/exclusion criteria for selecting subjects were fully
described in Ref.17

2.2. Rat experimental models
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Four-week old male and female Long Evans rats were fed isocaloric liquid diets
containing 0% or 26% ethanol for 8 weeks (n = 12 per group). During the last three
weeks of the experiment, EtOH exposed rats were binged with 2 g/kg EtOH via oral
gavage on Tuesdays, Thursdays, and Saturdays; controls were treated with saline. At
the end of the experiment, rats were deeply anesthetized with isofluorane and
exsanguinated by cardiac puncture.

All experiments were performed following

protocols approved by Institutional Animal Care and Use Committee at the LifespanRhode Island Hospital, and conformed to guidelines established by the National
Institutes of Health.

2.3. Human and rat tissue lysis and digestion
Rat and human tissue lysis and digestion method was carried out according to the
procedure described by Shao et al

18

.

Sample lysis and protein digestion were

performed in the Barocycler® 2320 EXT (Pressure Biosciences; West Bridgewater,
MA). Tissue samples were prepared with a PCT MicroPestle. Briefly, tissue pieces
including rat stomach, ileum, proximal colon (pCol), and distal colon (dCol) as well as
human sigmoids (1–5 mg) were placed in microTubes (Pressure BioSciences) with a
PCT-MicroPestle (Pressure BioSciences) in 25 μL of lysis buffer. The lysis buffer for
all samples contained 8 M urea in 100 mM ammonium bicarbonate. Samples were
sonicated on ice in the microTubes three times for 10 s. After sonication, sample lysis
and protein extraction were performed with a PCT-MicroPestle using 60 pressure
cycles, each consisting of 50 s of 45,000 psi (high pressure) and 10 s of atmospheric
pressure at 33 °C in the Barocycler. The supernatant was collected for BCA protein
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assay (Section 2.5). Thereafter, proteins were ready for digestion step. For protein
reduction and alkylation, TCEP (tris(2-carboxyethyl)phosphine) (10 mM) and
iodoacetamide (40 mM) were added to the solution for 30 min of incubation in the
dark at room temperature. After the replacement of the PCT-MicroPestle with a PCTMicroCap (150 μL size), samples were diluted with 100mM ammonium bicarbonate
to (75 µL) to reduce the urea concentration to 2 M prior to digestion with trypsin (10
µL, 1 mg/mL). Digestion was performed in the Barocycler at 33 °C using 45 cycles,
each consisting of 50 s at 20 000 psi (high pressure) and 10 s at atmospheric pressure.
Subsequently, second trypsin (10 µL, 1 mg/mL) digestion was carried out in the
Barocycler with a PCT-MicroCap (size 150 μL) under the condition of 90 cycles, each
consisting of 50 s at 20 000 psi (high pressure) and 10 s at atmospheric pressure at 33
°C. Thereafter, digestion was stopped by 12% formic acid (Optima™ LC-MS/MS
grade, Fisher Scientific). The peptides were stored in −80 °C before SWATH-MS
analysis. Figure 1 shows a schematic illustration of the experimental procedure from
tissue lysis and protein digestion to injection of samples to LC-MS/MS and data
analysis.

2.4. Protein and peptide concentration measure ment
Protein concentration was determined using Pierce™ Micro BCA protein assay
kit (Thermo Fisher Scientific, Rockford, IL, USA) with a Molecular Device
SpectraMax® M 5 plate reader (Molecular Devices, Sunnyvale, CA) by measuring
UV-vis absorbance at wavelength of 562 nm. A protease-free bovine serum albumin
(BSA) solution (2–40 µg/mL) was used as the standard calibration line for the BCA
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protein quantification method. MS-ready peptides were dissolved in deionized water
with 0.4% formic acid and measured with a NanoDrop 1000 spectrophotometer
(Thermo Scientific) at 280 nm (1 Ab = 1 mg/mL).

2.5. Triple-TOF MS analysis in SWATH mode
The SWATH-MS proteomics analysis and data processing were accomplished
based on the previously published method.19, 20 Briefly, A SCIEX 5600 TripleTOF
mass spectrometer equipped with a DuoSpray ion source (SCIEX, Concord, Canada)
coupled to Acquity UHPLC HClass system (Waters Corp., Milford, MA, USA) was
used. The mass spectrometer was operated in positive electrospray ionization (ESI)
mode for all the experiments. Compound and source/gas parameters used in SWATHMS method were as follows: DP = 120 V, CE = 10 V, collision energy spread (CES =
5V), TEM = 400 °C, ISVF = 5500 V, GS1 = 55 psi, and GS2 = 60 psi. TOF masses
were collected from m/z 300 to 1500. SWATH data was acquired in the range of m/z
400 to 1100 over 70 SWATH windows per cycles with a window size of m/z 10. The
total cycle time for SWATH acquisition was 3.95 sec.
The digested P-gp peptides were separated on an Acquity UHPLC Peptide BEH
C18 (2.1 × 150 mm2 , 300 Å, 1.7 μm) equipped with Acquity VanGuard precolumn
(2.1 × 5 mm2 , 300 Å, 1.7 μm). Autosampler temperature was kept at 10 °C and the
column temperature was maintained at 40 °C during all injections.

The

chromatographic separation was performed with a runtime of 120 min at 100 μL/min
with a gradient method using mobile phase A (98% water, 2% acetonitrile, 0.1%
formic acid) and mobile phase B (98% acetonitrile, 2% water, 0.1% formic acid). A
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gradient chromatographic elusion method was performed as follows: 98% A from 0 to
3 min, 60% to 90% A from 3 to 48 min, 20% A held from 49 to 52 min to flush the
column, 98% A at 53 min. The column was equilibrated at 98% A from 53 to 60 min
before the start of next run. The amount of protein per injection on the column was 10
μg. In each batch, trypsin-digested β- galactosidase that is a quality control standard
(1.65 pmol/injection) was injected to each sample to monitor mass calibration of the
TOF detector and normalization of peptides intensity in SWATH label free
quantification (LFQ) approach. The LFQ was performed using Skyline, which is an
open source application for targeted proteomics quantitative data analysis.

2.6. Statistical Analysis
The normality of data sets in each experiment was checked with Shapiro-Wilk
test. One-way analysis of variance (ANOVA) with Dunnett's T3 post hoc test (SPSS
23, SPSS, Inc.) was used for normally distributed observations. Kruskal-Wallis (KW)
one-way ANOVA (non-parametric ANOVA) with Dunn's multiple comparison post
hoc test was used in non-normally distributed data. In all analyses, probability values
<0.05 was considered significant.

3. Results and discussion
3.1. EtOH affects the expression of ALDH2 in human sigmoid colon
The expression level of proteins in sigmoid samples of ALD, AWLDLQ,
AWLDHQ, and HC subjects has been investigated by SWATH-MS proteomics. The
fold changes in proteins expression are mentioned in Table 1. According to the
results, the expression of the most proteins was not significantly altered in alcoholic
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subjects versus HC. However, aldehyde dehydrogenase2 (ALDH2), filamin A, and
glutathione S-transferase A1 (GSTA1) showed significant differences across groups.
ALDH2 detoxifies acetaldehyde (major EtOH metabolite) into acetate. The role
of ALDH2 in metabolism of EtOH inside the cells has been illustrated in Figure 2.21
Many studies on mice models have shown that ALDH2 overexpression in liver cells
ameliorates the pathological damages induced by chronic EtOH intake.22 Moreover,
Chaudhry and co-workers have shown that ALDH2 deficiency enhances EtOHinduced disruption of paracellular barriers in alcohol- fed mice models.23

In our

proteomics results, expression of ALDH2 in ALD and AWLDHQ was insignificantly
lower than that in HC group (Table 1). Progression of alcoholism to liver disease in
ALD subjects as well as higher paracellular damage in AWLDHQ group might be
induced due to the lower ALDH2 expression. In contrast, AWLDLQ subjects showed
significantly higher expression of ALDH2 compared to the HC. More expression of
ALDH2 in AWLDLQ patients might be the reason for retaining paracellular integrity
in these subjects.
Figure 3a shows a Box-plot illustrating the relative abundance of ALDH2 across
four groups of subjects.

KW with Dunn’s post hoc test showed that there is

statistically significant difference in expression of ALDH2 across AWLDHQ versus
AWLDLQ subjects (P- value = 0.005). Higher expression of ALDH2 in AWLDLQ
subjects may explain why paracellular barrier in these subjects is more integrated than
that in AWLDHQ.

3.2. EtOH affects the expression of GSTA1 in human sigmoid
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Figure 3b shows a Box-plot illustrating the relative abundance of GSATA1
across four groups of subjects. KW with Dunn’s post hoc test showed that there is
statistically significant difference in expression of GSTA1 across ALD versus
AWLDLQ subjects (P-value = 0.02).

According to the Table 1, the GSTA1

expression in ALD subjects was insignificantly lower than that in HC (P = 0.23). It
was previously indicated by Ma and co-workers that GSTA1 is downregulated in
EtOH- induced in mice model.24

In that study, the protective role of GSTA1 in

scavenging the free radicals generated by EtOH was suggested to justify the GSTA1
release from liver. The lower expression of GSTA1 in sigmoid samples of ALD
subjects was confirmed in our proteomics study. However, the expression level of
GSTA1 in AWLDLQ was higher than that in HC (Table 1). Sigmoid colon in
AWLDLQ subjects is possibly less affected by reactive oxygen species generated by
EtOH consumption. Enhanced expression of GSTA1 in AWLDLQ may suggest the
different role of this enzyme in EtOH- induced injury in GI tract compared to liver.

3.3. EtOH affects the expression of filamins in human sigmoid colon
Figure 4 shows the role of filamin A in relation to other cytoskeletal components.
The expression of filamin A is decreased in ALD, AWLDLQ, and AWLDHQ subjects
compares to the HC (Table 1). However, the reduction of filamin A expression was
statistically significant in AWLDLQ subjects (P-value = 0.05). Tobin and co-workers
have hypothesized that clinically relevant EtOH concentration (20–40 mM) disrupts
the mu-opioid receptor (MOP)- filamin A interaction 25 . Our results showed alteration
in the expression level of filamin A in alcoholic subjects compared to the HC group.
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According to our results, it could be suggested that diminished expression of filamin A
in alcoholic patients is probably the reason for disrupting MOP-filamin A interaction.
No significant difference was observed in the expression of any investigated
protein in ALD patients compared to the HC. The reason is the organ of analysis.
While, the site of EtOH- induced damage in these subjects is liver, proteomics analysis
of liver samples from ALD patients might be more relevant.

3.4. EtOH affects the expression of proteins in rat GI tract
The fold changes in proteins expression in stomach, ileum, pcolon, and d-Col of
EtOH-treated versus control rat groups are mentioned in Table 2. Results showed the
significant increase of vimentin in pCol region of alcoholic rat models (P-value =
0.05). Vimentin is an intermediate filament protein involved in cellular structure and
integrity. Induction of vimentin was not statistically significant in dCol (Table 2).
Results show expression of vimentin was not observed in stomach samples of control
and binge rats. Moreover, the vimentin expression was slightly decreased in ileum but
not statistically significant (P- value = 0.8).
Kelso et al have shown that vimentin is upregulated in binge rat models with
neurodegeration.26

They found that a prominent increase in vimentin expression

happened 4 and 7 days after the last EtOH dose. Duly and co-workers has shown that
binge alcohol rat models induced liver fibrogenesis by increasing the expression of
vimentin.27 in another study on alcohol- fed mice, Ambade et al have shown that
chronic EtOH exposure leads to vimentin upregulation.28 Although, these works had
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been done in brain and liver tissues, our pCol proteomics result is in agreement with
their findings.

4. Conclusion
SWATH-MS proteomics exhibits as a prominent technique in quantitative
analysis of proteins from limited biopsy samples.

In this work, the proteome of

human sigmoid colon biopsies as well as alcoholic rat GI tracts were studied. Results
show that the expression level of some proteins in sigmoidal colon samples of
alcoholic patients was altered compared to the healthy subjects.

Significant

differences were observed in expression of proteins in AWLDLQ subjects compare to
the HC. No significant difference was observed in the expression of any investigated
protein in ALD patients.

Moreover, the effect of chronic EtOH consumption on

proteins of different parts of GI tracts was examined in rat models. Vimentin and
desmin showed a significant induction in pCol of binge-chronic rat models compare to
the control group.

The power of SWATH-MS proteomics in analysis of clinical

biopsies might be helpful in identification of biomarkers to cure different stages of
alcoholism.
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Table IV- 1. Ratio of proteins expression in sigmoid colon of ALD, AWLDLQ, and
AWLDHQ versus HC of human subjects.

Protein name
Short-chain specific acyl-CoA
dehydrogenase
Very long-chain specific acyl-CoA
dehydrogenase
β-Actin
Beta-actin-like protein 2
Actin-2
Alcohol dehydrogenase 1B
Aldehyde dehydrogenase (mitochondrial)
Sodium/potassium-transporting ATPase
subunit α-1
Cadherin-17
Catenin β-1
Desmin
Desmoplakin
Fibronectin
Filamin-A
Glutathione S-transferase A1
Lamin-B1
Myosin-9
Spectrin β-chain
Spectrin α-chain
T ubulin alpha-1A
T ubulin alpha-1B
Villin-1
Vinculin

ALD/HC

Abundance ratio
PAWLDLQ /HC
value

P-value

ANLDHQ/
HC

Pvalue

0.72

0.91

2.11

0.16

0.27

0.16

0.81

1

5.62

0.07

0.74

0.74

0.83
0.82
0.82
0.95
0.85

0.83
1
0.83
0.13
0.59

1.22
0.97
1.12
1.15
5.21

0.52
0.91
0.67
0.13
0.02*

1.03
1.60
1.16
0.09
0.41

0.63
0.26
0.42
0.15
0.22

0.84

0.82

0.56

0.91

0.46

0.74

0.98
0.86
0.98
0.73
0.77
0.84
0.41
0.88
0.46
0.36
0.71
0.71
0.68
0.75
1.04

0.91
0.91
0.83
0.66
0.52
1
0.23
0.66
0.45
0.74
0.74
0.83
1
0.66
1

1.85
1.06
0.30
0.90
2.93
0.20
5.70
1.77
0.27
1.56
1.46
0.53
0.58
0.15
0.65

0.58
0.39
0.13
0.18
0.09
0.05*
0.03*
0.28
0.13
0.33
0.45
0.83
0.67
0.13
0.67

1.29
0.93
0.88
0.72
1.88
0.81
0.84
0.93
1.54
0.59
0.74
0.97
0.92
1.55
0.78

0.49
0.29
0.52
0.22
0.52
0.75
0.63
1
0.81
0.62
0.81
0.42
0.52
0.09
0.87

Abbreviation: HC: Healthy Control, AWLDLQ: Alcoholic Without Liver Disease
Low Quartile Sucralose, and AWLDHQ: Alcoholic Without Liver Disease High
Quartile Sucralose.
Non-parametric Mann–Whitney U test was used to determine the significance of
difference between ALD, AWLDLQ, and AWLDHQ groups versus healthy control
(HC) group, respectively. *Statistically significant decrease was observed in
expression of FLNA in AWLDLQ versus HC group. The expression of GSTA1, and
ALDH2 were significantly higher in AWLDLQ subjects compared to the HC group.
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Table IV- 2. Ratio of proteins expression in different gastrointestinal (GI) parts of EtOH- versus control- treated rats.
Abundance ratio
EP-value
dCol/CdColon
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Protein name

E-Stom/CStom

P-value

EIle/CIle

P-value

EpCol/CpCol

P-value

Sodiu m/potassium-transporting
ATPase subunit alpha-1

0.95

0.56

0.52

0.82

0.33

0.25

0.38

0.27

Cadherin-1

0.55

0.56

0.61

0.51

0.91

0.56

0.50

0.44

Cadherin-17
Aldehyde dehydrogenase,
mitochondrial
4-trimethylaminobutyraldehyde
dehydrogenase
Junction plakoglobin
Filamin-C
Vimentin
Actin, cytoplasmic 1
Annexin A 2
Vinculin
Actin, cytoplasmic 2
Tubulin alpha-1A chain
Tubulin alpha-1B chain

–

–

0.59

1.00

0.35

0.56

0.37

0.24

0.59

0.56

1.27

0.56

1.16

1.00

0.79

0.51

0.81

0.56

0.91

0.82

0.91

1.00

0.54

0.27

0.50
0.47
–
0.48
0.63
0.43
0.49
0.49
0.49

0.56
0.25
–
0.56
0.56
0.56
0.56
0.56
0.56

1.11
1.08
0.85
1.17
0.86
1.11
0.80
0.72
0.72

0.51
0.82
0.82
0.82
0.51
0.82
0.82
0.82
0.82

–
–
2.25
2.48
0.75
2.45
2.41
0.91
0.89

–
–
0.25
0.56
0.56
0.25
0.56
1.00
0.56

–
1.58
2.77
1.31
0.49
1.58
1.38
0.70
0.69

–
0.27
0.05*
0.27
0.27
0.27
0.27
0.51
0.51

Abbreviations: E-stom: stomach of EtOH-treated rats, C-Stom: stomach of control rats, E-Ile: ileum of EtOH-treated rats,
C-Ile: ileum of control rats, E-dCol: distal colon of EtOH-treated rats, C-dColon: distal colon of control rats, E-pCol:
proximal colon of EtOH-treated rats, C-pColon: proximal colon of control rats.
E-stom/C-Stom shows the fold change observed in the proteins abundance in stomach of EtOH-treated versus stomach of
control rat group. Likewise, E-Ile/C-Ile, E-dCol/C-dCol, and E-pCol/C-pCol show the fold change observed in the protein
abundance of Ile, dCol, and pCol from EtOH-treated versus control rat groups. Non-parametric Mann–Whitney U test was
used to determine the significance of difference between EtOH-treated groups versus control group in each part of GI tract.
*Statistically significant difference was observed in expression of Vim in alcohol-treated rats versus control groups.

Figure IV-1

Figure IV- 1. Schematic illustration of the experimental procedure to study rat and
human gastrointestinal (GI) tract samples by SWATH-MS approach.
Overview of the experimental procedure to study variable protein levels via SWATHMS proteomics over four different rat gastrointestinal segments (stomach, ileum,
proximal, and distal colon) as well as human sigmoid colon. Abbreviation: A:
ascending colon, T: transverse colon, D: descending colon, SWATH-MS: Sequential
Windowed data independent Acquisition of the Total High-resolution Mass Spectra,
PCT-MicroPestle: Pressure-cycling technology- MicroPestle.
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Figure IV-2

Figure IV- 2 Schematic illustration of ALDH2 in EtOH effects on different molecular
pathways.
The enzyme ALDH2 has been mentioned by a red line. The pathway is obtained from
Wikipathways (https://www.wikipathways.org).

122

Figure IV- 3

Figure IV- 3a) Box-plot of normalized aldehyde dehydrogenase2 (ALDH2) and b)
glutathione S-transferase A1 (GSTA1).
Protein abundance across control (HC), alcoholic with liver disease (ALD), alcoholic
without liver disease low quartile sucralose permeation (AWLDLQ), and alcoholic
without liver disease high quartile sucralose permeation (AWLDHQ) groups was
illustrated. Kruskal-Wallis H-test with post hoc Dunn’s was conducted to find out the
significance level among groups. The P-value of difference between AWLDLQ and
AWLDHQ subjects was 0.005. Furthermore, the P-value between AWLDLQ and
ALD was 0.02 for GSTA1.
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Figure IV-4

Figure IV- 4. Graphical representation of the Kyoto Encyclopedia of Genes and
Genomes (KEGG) for adherens junction pathway.
The role of filamin proteins in relation to other proteins has been illustrated. Filamin
A protein is shown by a red line.
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